{"timestamp": "2025-07-30T07:50:03.040340Z", "query": "What is Amivantamab used to treat?", "persona": "automatic", "intent": "classification_failed", "graph_suitable": "unknown", "tool_plan": [], "tool_results": [], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nAmivantamab is indicated for non-small cell lung cancer (NSCLC). <a href=\"URL_NOT_FOUND_IN_MANIFEST\" target=\"_blank\">March-2025-PBAC-Meeting (P...", "total_latency_sec": 17.891}
{"timestamp": "2025-07-30T08:53:25.011400Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_general_text", "estimated_coverage": 0.6}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: ABALOPARATIDE hassponsor THERAMEX AUSTRALIA PTY LTD.\nCitation: <a href=\"URL_NOT_FOUND_IN_MANIFEST\" target=\"_blank\">July-2025-PBAC-Meeting-v4 (Page 1-36)</a>", "estimated_coverage": 0.0}, {"tool_name": "retrieve_general_text", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe sponsor for Abaloparatide is Theramex Australia Pty Ltd. <a href=\"URL_NOT_FOUND_IN_MANIFEST\" target=\"_blank\">July-2025-PBAC-Meeting-v4...", "total_latency_sec": 15.087}
{"timestamp": "2025-07-30T08:53:45.268391Z", "query": "What is Amivantamab used to treat?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_clinical_data", "estimated_coverage": 0.7}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: AMIVANTAMAB hasindication Non-small cell lung cancer (NSCLC).\nCitation: <a href=\"URL_NOT_FOUND_IN_MANIFEST\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1-30)</a>", "estimated_coverage": 0.0}, {"tool_name": "retrieve_clinical_data", "success": true, "content": "Evidence from document: A\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: type psoriasis vulgaris | To request a General Schedule Restricted Benefit listing for the treatment of chronic plaque type psoriasis vulgaris in patients who have not adequately responded to potent topical corticosteroid monotherapy. |\n| ACTOR PHARMACEUTICALS PTY LTD |  |  |\n| (New PBS listing) CANNABIDIOL Oral liquid 100 mg per mL, 100 mL Epidyolex\u00ae JAZZ PHARMACEUTICALS ANZ PTY LTD | Seizures of the Lennox-Gastaut syndrome (LGS) | To request an amendment to the restriction level from Authority\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v4 (Page N/A)</a>\n---\nEvidence from document: lliative Care Authority Required (Telephone/Online) listing and a General Schedule Authority Required (STREAMLINED) listing of a new strength under the same conditions as the currently listed strength of methadone tablet for the management of severe disabling pain. |\n| (New PBS listing) |  |  |\n| MIRVETUXIMAB SORAVTANSINE |  |  |\n| Solution for I.V. infusion 100 mg in 20 mL vial Elahere\u00ae | Epithelial ovarian, fallopian tube or primary peritoneal cancer | To request a Section 100 (Efficient Fundi\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v4 (Page N/A)</a>\n---\nEvidence from document: o existing listing) | Small cell lung cancer (SCLC) | To request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (STREAMLINED) listing for the treatment of limited-stage SCLC in patients whose disease has not progressed during or following chemoradiation therapy. |\n\n8\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nJuly 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type \nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v4 (Page N/A)</a>\n---\nEvidence from document: uested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| INFLIXIMAB Powder for I.V. infusion 100 mg Ixifi\u00ae PFIZER AUSTRALIA PTY LTD ( New PBS listing) | Severe active rheumatoid arthritis Ankylosing spondylitis Severe psoriatic arthritis Severe chronic plaque psoriasis | To request Section 100 (Highly Specialised Drugs Program) Authority Severe Crohn disease, Required listings of a new infliximab\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: |  |  |\n\n13\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA May 2025 PBAC MEETING\n\nClosing date for consumer comments 26 March 2025\n\n| Review of antiepileptic drugs (AEDs) |  |  |\n|---|------|---|\n| Multiple Forms Multiple Brands Multiple Sponsors | Epilepsy | To consider amending the current PBS listings for the second-line AEDs, levetiracetam (LEV) and lamotrigine (LTG), to allow their first-line use in the general Australian population with epilepsy. |\n| (PBS review) Review \nCitation: <a href=\"#\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| ELACESTRANT |  |  |\n| Tablet 86 mg (as dihydrochloride) Tablet 345 mg (as dihydrochloride) Orserdu\u24c7 A. MENARINI AUSTRALIA PTY LTD | Est\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nAmivantamab is used to treat non-small cell lung cancer (NSCLC). <a href=\"URL_NOT_FOUND_IN_MANIFEST\" target=\"_blank\">March-2025-PBAC-Meeting (P...", "total_latency_sec": 12.537}
{"timestamp": "2025-07-30T22:18:57.996086Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "classification_failed", "graph_suitable": "unknown", "tool_plan": [], "tool_results": [], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nI had trouble understanding the sub-question....", "total_latency_sec": 152.567}
{"timestamp": "2025-07-31T07:59:31.309201Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_general_text", "estimated_coverage": 0.6}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: ABALOPARATIDE hassponsor THERAMEX AUSTRALIA PTY LTD.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1-38)</a>", "estimated_coverage": 0.0}, {"tool_name": "retrieve_general_text", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe sponsor for Abaloparatide is Theramex Australia Pty Ltd. <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing...", "total_latency_sec": 38.147}
{"timestamp": "2025-07-31T08:09:05.701417Z", "query": "What is Amivantamab used to treat?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_clinical_data", "estimated_coverage": 0.7}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: AMIVANTAMAB hasindication Non-small cell lung cancer (NSCLC).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1-30)</a>", "estimated_coverage": 0.0}, {"tool_name": "retrieve_clinical_data", "success": true, "content": "Evidence from document: ug Name, form(s), strength(s) and Sponsor, Submission type, PBS schedule (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission, requested authority level (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| DURVALUMAB Solution con\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: (Highly Specialised Drugs Program) |  |  |\n\n22\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA November 2025 PBAC MEETING\n\nClosing date for consumer comments 24 September 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type, PBS schedule (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission, requested authority level (Includes t\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: e/high-risk primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis. |\n| Inrebic\u00ae |  | Authority Required (Telephone/Online) |\n| BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |  |  |\n| (New PBS listing) |  |  |\n| PBS General Schedule FENFLURAMINE Oral solution 2.2 mg (as hydrochloride) per mL, 360 mL | Lennox-Gastaut Syndrome (LGS) | To request listing of fenfluramine as add-on therapy for patients with LGS who are not adequately controlled with at\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: uested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| INFLIXIMAB Powder for I.V. infusion 100 mg Ixifi\u00ae PFIZER AUSTRALIA PTY LTD ( New PBS listing) | Severe active rheumatoid arthritis Ankylosing spondylitis Severe psoriatic arthritis Severe chronic plaque psoriasis | To request Section 100 (Highly Specialised Drugs Program) Authority Severe Crohn disease, Required listings of a new infliximab\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: a. |\n|---|------|---|\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| Syfovre\u00ae APELLIS AUSTRALIA PTY LTD |  | Authority Required (Written or Telephone/Online) initial treatment Authority Required (STREAMLINED) for continuing treatment |\n| (New PBS listing) PBS General Schedule |  |  |\n\n14\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA November 2025 PBAC MEETING\n\nClosing date for consumer comments 24 September 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submis\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: |  |  |\n\n13\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA May 2025 PBAC MEETING\n\nClosing date for consumer comments 26 March 2025\n\n| Review of antiepileptic drugs (AEDs) |  |  |\n|---|------|---|\n| Multiple Forms Multiple Brands Multiple Sponsors | Epilepsy | To consider amending the current PBS listings for the second-line AEDs, levetiracetam (LEV) and lamotrigine (LTG), to allow their first-line use in the general Australian population with epilepsy. |\n| (PBS review) Review \nCitation: <a href=\"#\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| ELACESTRANT |  |  |\n| Tablet 86 mg (as dihydrochloride) Tablet 345 mg (as dihydrochloride) Orserdu\u24c7 A. MENARINI AUSTRALIA PTY LTD | Est\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nAmivantamab is used to treat non-small cell lung cancer (NSCLC). <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/...", "total_latency_sec": 31.495}
{"timestamp": "2025-07-31T08:10:02.675900Z", "query": "What is the trade name for Dostarlimab?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": false, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_clinical_data", "estimated_coverage": 0.7}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_clinical_data", "success": true, "content": "Evidence from document: nge to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| GUSELKUMAB |  |  |\n| Solution for I.V. infusion 200 mg in 20 mL vial Injection 100 mg in 1 mL single use pre-filled pen Injection 200 mg in 2 mL single use pre-filled pen, Injection 100 mg\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: s 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| ZOLBETUXIMAB |  |  |\n| Powder for I.V. in\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: AND PREDNISOLONE |  |  |\n| Pack containing 56 tablets abiraterone acetate 500 mg and 56 tablets prednisolone 5 mg Andriga-10 | Castration resistant metastatic carcinoma of the prostate (mCRPC) | To request a General Schedule Authority Required (Telephone/Online) listing of a composite pack containing abiraterone acetate and prednisolone for the treatment of patients with mCRPC. |\n| ACTOR PHARMACEUTICALS PTY LTD (New PBS listing) |  |  |\n| ACALABRUTINIB |  |  |\n| Tablet 100 mg Calquence\u00ae ASTRAZEN\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: COMMITTEE (PBAC) MEETING AGENDA\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) GEMCITABINE Solution for injection 1 g (as hydrochloride) in 25 mL Solution for injection 2 g (as hydrochloride) in 50 mL Gemcitabine Sandoz\u00ae SANDOZ PTY LTD (New PBS listing) INFLIXIMAB Solution for injection 120 mg in 1 mL pre- filled pen Soluti\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: e/high-risk primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis. |\n| Inrebic\u00ae |  | Authority Required (Telephone/Online) |\n| BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |  |  |\n| (New PBS listing) |  |  |\n| PBS General Schedule FENFLURAMINE Oral solution 2.2 mg (as hydrochloride) per mL, 360 mL | Lennox-Gastaut Syndrome (LGS) | To request listing of fenfluramine as add-on therapy for patients with LGS who are not adequately controlled with at\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: tablets of elexacaftor 50 |  |  |\n| mg with tezacaftor 25 mg and ivacaftor 37.5 |  |  |\n| mg and 28 tablets of ivacaftor 75 mg |  |  |\n| Pack containing 28 sachets elexacaftor 100 mg with tezacaftor 50 mg and with ivacaftor |  |  |\n| 75 mg and 28 sachets ivacaftor 75 mg |  |  |\n| Pack containing 28 sachets elexacaftor 80 |  |  |\n| mg with tezacaftor 40 mg and with ivacaftor 60 mg and 28 sachets ivacaftor 59.5 mg |  |  |\n| Trikafta\u24c7 |  |  |\n| VERTEX PHARMACEUTICALS (AUSTRALIA) PTY. LTD. (DUSC ana\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: a. |\n|---|------|---|\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| Syfovre\u00ae APELLIS AUSTRALIA PTY LTD |  | Authority Required (Written or Telephone/Online) initial treatment Authority Required (STREAMLINED) for continuing treatment |\n| (New PBS listing) PBS General Schedule |  |  |\n\n14\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA November 2025 PBAC MEETING\n\nClosing date for consumer comments 24 September 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submis\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nThe provided text does not contain the trade name for Dostarlimab.  Therefore, I cannot answer your question.\n\n### References\nNo references wer...", "total_latency_sec": 22.675}
{"timestamp": "2025-07-31T08:10:30.114568Z", "query": "What is the dosage form of Apomorphine?", "persona": "automatic", "intent": "classification_failed", "graph_suitable": "unknown", "tool_plan": [], "tool_results": [], "final_answer_preview": "N/A", "total_latency_sec": 19.758}
{"timestamp": "2025-07-31T08:18:07.173558Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_general_text", "estimated_coverage": 0.6}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: ABALOPARATIDE hassponsor THERAMEX AUSTRALIA PTY LTD.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1-38)</a>", "estimated_coverage": 0.0}, {"tool_name": "retrieve_general_text", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe sponsor for Abaloparatide is Theramex Australia Pty Ltd. <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing...", "total_latency_sec": 29.92}
{"timestamp": "2025-07-31T08:27:41.421479Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_general_text", "estimated_coverage": 0.6}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "A complex relationship was found in the graph.", "estimated_coverage": 0.0}, {"tool_name": "retrieve_general_text", "success": false, "content": "An error occurred: name 'genai' is not defined", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe provided evidence does not contain information about the sponsor of Abaloparatide.  Therefore, I cannot answer your question.\n\n### Ref...", "total_latency_sec": 9.786}
{"timestamp": "2025-07-31T08:29:29.134847Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_general_text", "estimated_coverage": 0.6}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "A complex relationship was found in the graph.", "estimated_coverage": 0.0}, {"tool_name": "retrieve_general_text", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe provided text does not contain information about the sponsor of Abaloparatide.  Therefore, I cannot answer your question.\n\n### Referen...", "total_latency_sec": 16.619}
{"timestamp": "2025-07-31T08:31:29.547751Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_general_text", "estimated_coverage": 0.6}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "A complex relationship was found in the graph.", "estimated_coverage": 0.0}, {"tool_name": "retrieve_general_text", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe provided evidence does not contain information about the sponsor of Abaloparatide.  Therefore, I cannot answer your question.\n\n### Ref...", "total_latency_sec": 13.866}
{"timestamp": "2025-07-31T08:44:02.032805Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_general_text", "estimated_coverage": 0.6}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "A complex relationship was found in the graph.", "estimated_coverage": 0.0}, {"tool_name": "retrieve_general_text", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe provided text does not contain information about the sponsor of Abaloparatide.  Therefore, I cannot answer your question.\n\n### Referen...", "total_latency_sec": 9.188}
{"timestamp": "2025-07-31T08:49:12.435469Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_general_text", "estimated_coverage": 0.6}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "A complex relationship was found in the graph.", "estimated_coverage": 0.0}, {"tool_name": "retrieve_general_text", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe provided evidence does not contain the answer.\n...", "total_latency_sec": 10.159}
{"timestamp": "2025-07-31T08:51:12.285678Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_general_text", "estimated_coverage": 0.6}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_general_text", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nI searched but could not find any relevant details for this step....", "total_latency_sec": 7.884}
{"timestamp": "2025-07-31T08:53:02.402579Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_general_text", "estimated_coverage": 0.6}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: ABALOPARATIDE hassponsor THERAMEX AUSTRALIA PTY LTD.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1-38)</a>", "estimated_coverage": 0.0}, {"tool_name": "retrieve_general_text", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe sponsor for Abaloparatide is Theramex Australia Pty Ltd. <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing...", "total_latency_sec": 8.552}
{"timestamp": "2025-07-31T08:53:39.126981Z", "query": "What is Amivantamab used to treat?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_clinical_data", "estimated_coverage": 0.7}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: AMIVANTAMAB hasindication Non-small cell lung cancer (NSCLC).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1-30)</a>", "estimated_coverage": 0.0}, {"tool_name": "retrieve_clinical_data", "success": true, "content": "Evidence from document: ug Name, form(s), strength(s) and Sponsor, Submission type, PBS schedule (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission, requested authority level (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| DURVALUMAB Solution con\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: (Highly Specialised Drugs Program) |  |  |\n\n22\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA November 2025 PBAC MEETING\n\nClosing date for consumer comments 24 September 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type, PBS schedule (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission, requested authority level (Includes t\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: e/high-risk primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis. |\n| Inrebic\u00ae |  | Authority Required (Telephone/Online) |\n| BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |  |  |\n| (New PBS listing) |  |  |\n| PBS General Schedule FENFLURAMINE Oral solution 2.2 mg (as hydrochloride) per mL, 360 mL | Lennox-Gastaut Syndrome (LGS) | To request listing of fenfluramine as add-on therapy for patients with LGS who are not adequately controlled with at\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: uested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| INFLIXIMAB Powder for I.V. infusion 100 mg Ixifi\u00ae PFIZER AUSTRALIA PTY LTD ( New PBS listing) | Severe active rheumatoid arthritis Ankylosing spondylitis Severe psoriatic arthritis Severe chronic plaque psoriasis | To request Section 100 (Highly Specialised Drugs Program) Authority Severe Crohn disease, Required listings of a new infliximab\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: a. |\n|---|------|---|\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| Syfovre\u00ae APELLIS AUSTRALIA PTY LTD |  | Authority Required (Written or Telephone/Online) initial treatment Authority Required (STREAMLINED) for continuing treatment |\n| (New PBS listing) PBS General Schedule |  |  |\n\n14\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA November 2025 PBAC MEETING\n\nClosing date for consumer comments 24 September 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submis\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: |  |  |\n\n13\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA May 2025 PBAC MEETING\n\nClosing date for consumer comments 26 March 2025\n\n| Review of antiepileptic drugs (AEDs) |  |  |\n|---|------|---|\n| Multiple Forms Multiple Brands Multiple Sponsors | Epilepsy | To consider amending the current PBS listings for the second-line AEDs, levetiracetam (LEV) and lamotrigine (LTG), to allow their first-line use in the general Australian population with epilepsy. |\n| (PBS review) Review \nCitation: <a href=\"#\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| ELACESTRANT |  |  |\n| Tablet 86 mg (as dihydrochloride) Tablet 345 mg (as dihydrochloride) Orserdu\u24c7 A. MENARINI AUSTRALIA PTY LTD | Est\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nAmivantamab is used to treat Non-small cell lung cancer (NSCLC). <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/...", "total_latency_sec": 5.364}
{"timestamp": "2025-07-31T08:53:54.860128Z", "query": "What is the trade name for Dostarlimab?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": false, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_clinical_data", "estimated_coverage": 0.7}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_clinical_data", "success": true, "content": "Evidence from document: nge to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| GUSELKUMAB |  |  |\n| Solution for I.V. infusion 200 mg in 20 mL vial Injection 100 mg in 1 mL single use pre-filled pen Injection 200 mg in 2 mL single use pre-filled pen, Injection 100 mg\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: s 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| ZOLBETUXIMAB |  |  |\n| Powder for I.V. in\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: AND PREDNISOLONE |  |  |\n| Pack containing 56 tablets abiraterone acetate 500 mg and 56 tablets prednisolone 5 mg Andriga-10 | Castration resistant metastatic carcinoma of the prostate (mCRPC) | To request a General Schedule Authority Required (Telephone/Online) listing of a composite pack containing abiraterone acetate and prednisolone for the treatment of patients with mCRPC. |\n| ACTOR PHARMACEUTICALS PTY LTD (New PBS listing) |  |  |\n| ACALABRUTINIB |  |  |\n| Tablet 100 mg Calquence\u00ae ASTRAZEN\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: COMMITTEE (PBAC) MEETING AGENDA\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) GEMCITABINE Solution for injection 1 g (as hydrochloride) in 25 mL Solution for injection 2 g (as hydrochloride) in 50 mL Gemcitabine Sandoz\u00ae SANDOZ PTY LTD (New PBS listing) INFLIXIMAB Solution for injection 120 mg in 1 mL pre- filled pen Soluti\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: e/high-risk primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis. |\n| Inrebic\u00ae |  | Authority Required (Telephone/Online) |\n| BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |  |  |\n| (New PBS listing) |  |  |\n| PBS General Schedule FENFLURAMINE Oral solution 2.2 mg (as hydrochloride) per mL, 360 mL | Lennox-Gastaut Syndrome (LGS) | To request listing of fenfluramine as add-on therapy for patients with LGS who are not adequately controlled with at\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: tablets of elexacaftor 50 |  |  |\n| mg with tezacaftor 25 mg and ivacaftor 37.5 |  |  |\n| mg and 28 tablets of ivacaftor 75 mg |  |  |\n| Pack containing 28 sachets elexacaftor 100 mg with tezacaftor 50 mg and with ivacaftor |  |  |\n| 75 mg and 28 sachets ivacaftor 75 mg |  |  |\n| Pack containing 28 sachets elexacaftor 80 |  |  |\n| mg with tezacaftor 40 mg and with ivacaftor 60 mg and 28 sachets ivacaftor 59.5 mg |  |  |\n| Trikafta\u24c7 |  |  |\n| VERTEX PHARMACEUTICALS (AUSTRALIA) PTY. LTD. (DUSC ana\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: a. |\n|---|------|---|\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| Syfovre\u00ae APELLIS AUSTRALIA PTY LTD |  | Authority Required (Written or Telephone/Online) initial treatment Authority Required (STREAMLINED) for continuing treatment |\n| (New PBS listing) PBS General Schedule |  |  |\n\n14\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA November 2025 PBAC MEETING\n\nClosing date for consumer comments 24 September 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submis\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nThe provided evidence does not contain the answer.\n...", "total_latency_sec": 3.622}
{"timestamp": "2025-07-31T08:54:02.956974Z", "query": "What is the dosage form of Apomorphine?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": false, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_clinical_data", "estimated_coverage": 0.7}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_clinical_data", "success": true, "content": "Evidence from document: e (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission, requested authority level (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| OMAVELOXOLONE Capsule 50 mg | Friedreich's ataxia | Resubmission to request listing of omavelo\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: tablets of elexacaftor 50 |  |  |\n| mg with tezacaftor 25 mg and ivacaftor 37.5 |  |  |\n| mg and 28 tablets of ivacaftor 75 mg |  |  |\n| Pack containing 28 sachets elexacaftor 100 mg with tezacaftor 50 mg and with ivacaftor |  |  |\n| 75 mg and 28 sachets ivacaftor 75 mg |  |  |\n| Pack containing 28 sachets elexacaftor 80 |  |  |\n| mg with tezacaftor 40 mg and with ivacaftor 60 mg and 28 sachets ivacaftor 59.5 mg |  |  |\n| Trikafta\u24c7 |  |  |\n| VERTEX PHARMACEUTICALS (AUSTRALIA) PTY. LTD. (DUSC ana\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| ELACESTRANT |  |  |\n| Tablet 86 mg (as dihydrochloride) Tablet 345 mg (as dihydrochloride) Orserdu\u24c7 A. MENARINI AUSTRALIA PTY LTD | Est\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: LINED) listing for the treatment of patients with extensive-stage small-cell lung cancer with disease progression after platinum-based chemotherapy and at least one other line of therapy (i.e. third- line therapy or thereafter). |\n|  |  |  |\n| WITHDRAWN |  |  |\n| TERIPARATIDE |  |  |\n| Injection 250 micrograms per mL, 2.4 mL in multi-dose pre-filled pen Ritosa\u24c7 SUN PHARMA ANZ PTY LTD (New PBS listing) | Osteoporosis | To request a General Schedule Authority Required (STREAMLINED) listing under t\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LTD | Advanced systemic mastocytosis | To request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for the treatment of adult patients with advanced systemic mastocytosis. |\n| (Change to existing listing) MOGAMULIZUMAB |  |  |\n| Solution concentrate for I.V. infusion 20 mg in 5 mL Poteligeo\u24c7 KYOWA KIRIN AUSTRALIA PTY LTD (New PBS listing) NATALIZUMAB | Cutaneous T-cell lymphoma (CTCL) | Resubmission to request a Section \nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: uested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| INFLIXIMAB Powder for I.V. infusion 100 mg Ixifi\u00ae PFIZER AUSTRALIA PTY LTD ( New PBS listing) | Severe active rheumatoid arthritis Ankylosing spondylitis Severe psoriatic arthritis Severe chronic plaque psoriasis | To request Section 100 (Highly Specialised Drugs Program) Authority Severe Crohn disease, Required listings of a new infliximab\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: COMMITTEE (PBAC) MEETING AGENDA\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) GEMCITABINE Solution for injection 1 g (as hydrochloride) in 25 mL Solution for injection 2 g (as hydrochloride) in 50 mL Gemcitabine Sandoz\u00ae SANDOZ PTY LTD (New PBS listing) INFLIXIMAB Solution for injection 120 mg in 1 mL pre- filled pen Soluti\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nThe provided evidence does not contain the answer.\n...", "total_latency_sec": 3.803}
{"timestamp": "2025-07-31T10:10:04.505496Z", "query": "Which sponsors made submissions in both the March 2025 and July 2025 meetings?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_general_text", "estimated_coverage": 0.6}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_general_text", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nI searched but could not find any relevant details for this step....", "total_latency_sec": 9.285}
{"timestamp": "2025-07-31T10:10:05.810350Z", "query": "What is the trade name for Dostarlimab?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": false, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_clinical_data", "estimated_coverage": 0.7}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_clinical_data", "success": true, "content": "Evidence from document: nge to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| GUSELKUMAB |  |  |\n| Solution for I.V. infusion 200 mg in 20 mL vial Injection 100 mg in 1 mL single use pre-filled pen Injection 200 mg in 2 mL single use pre-filled pen, Injection 100 mg\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: s 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| ZOLBETUXIMAB |  |  |\n| Powder for I.V. in\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: AND PREDNISOLONE |  |  |\n| Pack containing 56 tablets abiraterone acetate 500 mg and 56 tablets prednisolone 5 mg Andriga-10 | Castration resistant metastatic carcinoma of the prostate (mCRPC) | To request a General Schedule Authority Required (Telephone/Online) listing of a composite pack containing abiraterone acetate and prednisolone for the treatment of patients with mCRPC. |\n| ACTOR PHARMACEUTICALS PTY LTD (New PBS listing) |  |  |\n| ACALABRUTINIB |  |  |\n| Tablet 100 mg Calquence\u00ae ASTRAZEN\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: COMMITTEE (PBAC) MEETING AGENDA\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) GEMCITABINE Solution for injection 1 g (as hydrochloride) in 25 mL Solution for injection 2 g (as hydrochloride) in 50 mL Gemcitabine Sandoz\u00ae SANDOZ PTY LTD (New PBS listing) INFLIXIMAB Solution for injection 120 mg in 1 mL pre- filled pen Soluti\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: e/high-risk primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis. |\n| Inrebic\u00ae |  | Authority Required (Telephone/Online) |\n| BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |  |  |\n| (New PBS listing) |  |  |\n| PBS General Schedule FENFLURAMINE Oral solution 2.2 mg (as hydrochloride) per mL, 360 mL | Lennox-Gastaut Syndrome (LGS) | To request listing of fenfluramine as add-on therapy for patients with LGS who are not adequately controlled with at\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: tablets of elexacaftor 50 |  |  |\n| mg with tezacaftor 25 mg and ivacaftor 37.5 |  |  |\n| mg and 28 tablets of ivacaftor 75 mg |  |  |\n| Pack containing 28 sachets elexacaftor 100 mg with tezacaftor 50 mg and with ivacaftor |  |  |\n| 75 mg and 28 sachets ivacaftor 75 mg |  |  |\n| Pack containing 28 sachets elexacaftor 80 |  |  |\n| mg with tezacaftor 40 mg and with ivacaftor 60 mg and 28 sachets ivacaftor 59.5 mg |  |  |\n| Trikafta\u24c7 |  |  |\n| VERTEX PHARMACEUTICALS (AUSTRALIA) PTY. LTD. (DUSC ana\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: a. |\n|---|------|---|\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| Syfovre\u00ae APELLIS AUSTRALIA PTY LTD |  | Authority Required (Written or Telephone/Online) initial treatment Authority Required (STREAMLINED) for continuing treatment |\n| (New PBS listing) PBS General Schedule |  |  |\n\n14\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA November 2025 PBAC MEETING\n\nClosing date for consumer comments 24 September 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submis\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nThe provided evidence does not contain the answer.\n...", "total_latency_sec": 4.795}
{"timestamp": "2025-07-31T10:10:12.843992Z", "query": "Which sponsors made submissions in both the March 2025 and July 2025 meetings?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_general_text", "estimated_coverage": 0.6}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_general_text", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nI searched but could not find any relevant details for this step....", "total_latency_sec": 4.912}
{"timestamp": "2025-07-31T10:10:21.003823Z", "query": "Compare the submission purposes for Acalabrutinib and Alectinib in the 2025 meetings.", "persona": "automatic", "intent": "comparative_analysis", "graph_suitable": true, "tool_plan": [{"tool_name": "retrieve_general_text", "estimated_coverage": 0.7}, {"tool_name": "retrieve_summary_data", "estimated_coverage": 0.64}], "tool_results": [{"tool_name": "retrieve_general_text", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_summary_data", "success": true, "content": "Evidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: The table presents the agenda for the November 2025 PBAC meeting, including submissions for changes to existing listings and new listings for National Immunisation Program (NIP) inclusion.  GlaxoSmithKline Australia Pty Ltd requests a change to the existing NIP listing for Shingrix\u00ae, a recombinant zoster vaccine, to lower the eligible age for non-Indigenous adults from 65 to 60 years. Moderna Australia Pty Ltd seeks a new NIP listing for mResvia\u00ae, a respiratory syncytial virus (RSV) vaccine, for\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including drug submissions for Durvalumab and Enoxaparin. Durvalumab's submission seeks a streamlined authority required listing for limited-stage small cell lung cancer (SCLC) in patients with stable disease post-chemoradiation. Enoxaparin's submission covers various indications related to venous thromboembolism (VTE) prevention and treatment, extracorporeal thrombosis prevention during haemodialysis, and acute ST-segment elevation t\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: The table presents the agenda for the March 2025 PBAC meeting, detailing new drug submissions and listing requests.  It includes drugs like Dupilumab (Dupixent\u00ae) for atopic dermatitis and asthma in children, Efgartigimod alfa (Vyvgart\u00ae) for myasthenia gravis, and Eflornithine (Ifinwil\u00ae) for neuroblastoma.\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: The table presents the agenda for the May 2025 PBAC meeting, detailing submissions for new or amended listings of Repotrectinib, Teprotumumab, and Trastuzumab Deruxtecan for various cancer and thyroid eye disease indications. The meeting also includes a submission for Ublituximab for relapsing-remitting multiple sclerosis.\nCitation: <a href=\"#\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Ph\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe provided evidence does not contain the answer.\n...", "total_latency_sec": 5.4}
{"timestamp": "2025-07-31T10:10:30.212270Z", "query": "What is the indication for the drug whose trade name is Cabometyx?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_clinical_data", "estimated_coverage": 0.7}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_clinical_data", "success": true, "content": "Evidence from document: e/high-risk primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis. |\n| Inrebic\u00ae |  | Authority Required (Telephone/Online) |\n| BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |  |  |\n| (New PBS listing) |  |  |\n| PBS General Schedule FENFLURAMINE Oral solution 2.2 mg (as hydrochloride) per mL, 360 mL | Lennox-Gastaut Syndrome (LGS) | To request listing of fenfluramine as add-on therapy for patients with LGS who are not adequately controlled with at\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: AND PREDNISOLONE |  |  |\n| Pack containing 56 tablets abiraterone acetate 500 mg and 56 tablets prednisolone 5 mg Andriga-10 | Castration resistant metastatic carcinoma of the prostate (mCRPC) | To request a General Schedule Authority Required (Telephone/Online) listing of a composite pack containing abiraterone acetate and prednisolone for the treatment of patients with mCRPC. |\n| ACTOR PHARMACEUTICALS PTY LTD (New PBS listing) |  |  |\n| ACALABRUTINIB |  |  |\n| Tablet 100 mg Calquence\u00ae ASTRAZEN\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: uested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| INFLIXIMAB Powder for I.V. infusion 100 mg Ixifi\u00ae PFIZER AUSTRALIA PTY LTD ( New PBS listing) | Severe active rheumatoid arthritis Ankylosing spondylitis Severe psoriatic arthritis Severe chronic plaque psoriasis | To request Section 100 (Highly Specialised Drugs Program) Authority Severe Crohn disease, Required listings of a new infliximab\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: ug Name, form(s), strength(s) and Sponsor, Submission type, PBS schedule (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission, requested authority level (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| DURVALUMAB Solution con\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: COMMITTEE (PBAC) MEETING AGENDA\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) GEMCITABINE Solution for injection 1 g (as hydrochloride) in 25 mL Solution for injection 2 g (as hydrochloride) in 50 mL Gemcitabine Sandoz\u00ae SANDOZ PTY LTD (New PBS listing) INFLIXIMAB Solution for injection 120 mg in 1 mL pre- filled pen Soluti\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: multi-dose pre-filled pen, 4 doses |  |  |\n| Mounjaro\u00ae KwikPen\u00ae |  |  |\n| ELI LILLY AUSTRALIA PTY LTD |  |  |\n| (New PBS listing) |  |  |\n\n28\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nJuly 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) VANZACAFTOR WITH TEZACAFTOR AND WITH DEUTIVACAFTOR Pack containing 84 table\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: | (New PBS listing) PBS General Schedule |  |  |\n\n18\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA November 2025 PBAC MEETING\n\nClosing date for consumer comments 24 September 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type, PBS schedule (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission, requested authority level (Incl\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nThe provided evidence does not contain the answer.\n...", "total_latency_sec": 5.125}
{"timestamp": "2025-07-31T10:10:42.353600Z", "query": "Provide a summary of the key submissions from the May 2025 PBAC meeting.", "persona": "automatic", "intent": "simple_summary", "graph_suitable": false, "tool_plan": [{"tool_name": "retrieve_general_text", "estimated_coverage": 0.8}, {"tool_name": "retrieve_summary_data", "estimated_coverage": 0.72}], "tool_results": [{"tool_name": "retrieve_general_text", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_summary_data", "success": true, "content": "Evidence from document: The table presents the agenda for the November 2025 PBAC meeting, including submissions for changes to existing listings and new listings for National Immunisation Program (NIP) inclusion.  GlaxoSmithKline Australia Pty Ltd requests a change to the existing NIP listing for Shingrix\u00ae, a recombinant zoster vaccine, to lower the eligible age for non-Indigenous adults from 65 to 60 years. Moderna Australia Pty Ltd seeks a new NIP listing for mResvia\u00ae, a respiratory syncytial virus (RSV) vaccine, for\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: The May 2025 PBAC meeting agenda includes items related to a new listing request for RRMS treatment by Kirchmann Enterprises, review of ATAGI recommendations on pediatric pneumococcal schedule, utilization assessment of fluticasone furoate + umeclidinium + vilanterol for severe asthma, utilization review of medicines for gastrointestinal stromal tumour, and utilization review of zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia.\nCitation: <a href=\"#\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: The July 2025 PBAC meeting agenda includes Abaloparatide for the first-line treatment of severe established osteoporosis under a General Schedule Authority Required listing and Abiraterone Acetate, with further details to be provided in the subsequent table rows.\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Ph\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: The table presents an agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the Pharmaceutical Benefits Scheme (PBS). Submissions include Brexpiprazole for schizophrenia, Bulevirtide for chronic hepatitis D (resubmission), and Cabozantinib for pancreatic and extra-pancreatic neuroendocrine tumors. The closing date for consumer comments was May 28, 2025.\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe May 2025 PBAC meeting included submissions for a new listing request for RRMS treatment by Kirchmann Enterprises; review of ATAGI reco...", "total_latency_sec": 5.93}
{"timestamp": "2025-07-31T10:11:03.966519Z", "query": "Summarize all submissions related to oncology in the March 2025 documents.", "persona": "automatic", "intent": "simple_summary", "graph_suitable": false, "tool_plan": [{"tool_name": "retrieve_general_text", "estimated_coverage": 0.8}, {"tool_name": "retrieve_summary_data", "estimated_coverage": 0.72}], "tool_results": [{"tool_name": "retrieve_general_text", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_summary_data", "success": true, "content": "Evidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: The May 2025 PBAC meeting agenda includes items related to a new listing request for RRMS treatment by Kirchmann Enterprises, review of ATAGI recommendations on pediatric pneumococcal schedule, utilization assessment of fluticasone furoate + umeclidinium + vilanterol for severe asthma, utilization review of medicines for gastrointestinal stromal tumour, and utilization review of zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia.\nCitation: <a href=\"#\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: The table presents the agenda for the November 2025 PBAC meeting, including submissions for changes to existing listings and new listings for National Immunisation Program (NIP) inclusion.  GlaxoSmithKline Australia Pty Ltd requests a change to the existing NIP listing for Shingrix\u00ae, a recombinant zoster vaccine, to lower the eligible age for non-Indigenous adults from 65 to 60 years. Moderna Australia Pty Ltd seeks a new NIP listing for mResvia\u00ae, a respiratory syncytial virus (RSV) vaccine, for\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, including consumer comment deadlines and details of drug submissions.  It includes requests for changes to existing listings (e.g., Ranibizumab for proliferative diabetic retinopathy) and new listings (e.g., Raxtozinameran for COVID-19 prevention in specific adult populations).\nCitation: <a href=\"#\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"#\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Ph\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe provided evidence does not contain the answer.\n...", "total_latency_sec": 7.227}
{"timestamp": "2025-07-31T10:35:33.652225Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_general_text", "estimated_coverage": 0.6}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: ABALOPARATIDE hassponsor THERAMEX AUSTRALIA PTY LTD.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1-38)</a>", "estimated_coverage": 0.0}, {"tool_name": "retrieve_general_text", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe sponsor for Abaloparatide is Theramex Australia Pty Ltd. <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing...", "total_latency_sec": 13.167}
{"timestamp": "2025-07-31T10:35:45.605702Z", "query": "What is Amivantamab used to treat?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_clinical_data", "estimated_coverage": 0.7}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: AMIVANTAMAB hasindication Non-small cell lung cancer (NSCLC).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1-30)</a>", "estimated_coverage": 0.0}, {"tool_name": "retrieve_clinical_data", "success": true, "content": "Evidence from document: ug Name, form(s), strength(s) and Sponsor, Submission type, PBS schedule (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission, requested authority level (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| DURVALUMAB Solution con\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: (Highly Specialised Drugs Program) |  |  |\n\n22\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA November 2025 PBAC MEETING\n\nClosing date for consumer comments 24 September 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type, PBS schedule (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission, requested authority level (Includes t\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: e/high-risk primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis. |\n| Inrebic\u00ae |  | Authority Required (Telephone/Online) |\n| BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |  |  |\n| (New PBS listing) |  |  |\n| PBS General Schedule FENFLURAMINE Oral solution 2.2 mg (as hydrochloride) per mL, 360 mL | Lennox-Gastaut Syndrome (LGS) | To request listing of fenfluramine as add-on therapy for patients with LGS who are not adequately controlled with at\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: uested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| INFLIXIMAB Powder for I.V. infusion 100 mg Ixifi\u00ae PFIZER AUSTRALIA PTY LTD ( New PBS listing) | Severe active rheumatoid arthritis Ankylosing spondylitis Severe psoriatic arthritis Severe chronic plaque psoriasis | To request Section 100 (Highly Specialised Drugs Program) Authority Severe Crohn disease, Required listings of a new infliximab\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: a. |\n|---|------|---|\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| Syfovre\u00ae APELLIS AUSTRALIA PTY LTD |  | Authority Required (Written or Telephone/Online) initial treatment Authority Required (STREAMLINED) for continuing treatment |\n| (New PBS listing) PBS General Schedule |  |  |\n\n14\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA November 2025 PBAC MEETING\n\nClosing date for consumer comments 24 September 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submis\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: |  |  |\n\n13\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA May 2025 PBAC MEETING\n\nClosing date for consumer comments 26 March 2025\n\n| Review of antiepileptic drugs (AEDs) |  |  |\n|---|------|---|\n| Multiple Forms Multiple Brands Multiple Sponsors | Epilepsy | To consider amending the current PBS listings for the second-line AEDs, levetiracetam (LEV) and lamotrigine (LTG), to allow their first-line use in the general Australian population with epilepsy. |\n| (PBS review) Review \nCitation: <a href=\"#\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| ELACESTRANT |  |  |\n| Tablet 86 mg (as dihydrochloride) Tablet 345 mg (as dihydrochloride) Orserdu\u24c7 A. MENARINI AUSTRALIA PTY LTD | Est\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nAmivantamab is used to treat Non-small cell lung cancer (NSCLC). <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/...", "total_latency_sec": 6.185}
{"timestamp": "2025-07-31T10:35:53.645474Z", "query": "What is the trade name for Dostarlimab?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": false, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_clinical_data", "estimated_coverage": 0.7}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_clinical_data", "success": true, "content": "Evidence from document: nge to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| GUSELKUMAB |  |  |\n| Solution for I.V. infusion 200 mg in 20 mL vial Injection 100 mg in 1 mL single use pre-filled pen Injection 200 mg in 2 mL single use pre-filled pen, Injection 100 mg\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: s 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| ZOLBETUXIMAB |  |  |\n| Powder for I.V. in\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: AND PREDNISOLONE |  |  |\n| Pack containing 56 tablets abiraterone acetate 500 mg and 56 tablets prednisolone 5 mg Andriga-10 | Castration resistant metastatic carcinoma of the prostate (mCRPC) | To request a General Schedule Authority Required (Telephone/Online) listing of a composite pack containing abiraterone acetate and prednisolone for the treatment of patients with mCRPC. |\n| ACTOR PHARMACEUTICALS PTY LTD (New PBS listing) |  |  |\n| ACALABRUTINIB |  |  |\n| Tablet 100 mg Calquence\u00ae ASTRAZEN\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: COMMITTEE (PBAC) MEETING AGENDA\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) GEMCITABINE Solution for injection 1 g (as hydrochloride) in 25 mL Solution for injection 2 g (as hydrochloride) in 50 mL Gemcitabine Sandoz\u00ae SANDOZ PTY LTD (New PBS listing) INFLIXIMAB Solution for injection 120 mg in 1 mL pre- filled pen Soluti\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: e/high-risk primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis. |\n| Inrebic\u00ae |  | Authority Required (Telephone/Online) |\n| BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |  |  |\n| (New PBS listing) |  |  |\n| PBS General Schedule FENFLURAMINE Oral solution 2.2 mg (as hydrochloride) per mL, 360 mL | Lennox-Gastaut Syndrome (LGS) | To request listing of fenfluramine as add-on therapy for patients with LGS who are not adequately controlled with at\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: tablets of elexacaftor 50 |  |  |\n| mg with tezacaftor 25 mg and ivacaftor 37.5 |  |  |\n| mg and 28 tablets of ivacaftor 75 mg |  |  |\n| Pack containing 28 sachets elexacaftor 100 mg with tezacaftor 50 mg and with ivacaftor |  |  |\n| 75 mg and 28 sachets ivacaftor 75 mg |  |  |\n| Pack containing 28 sachets elexacaftor 80 |  |  |\n| mg with tezacaftor 40 mg and with ivacaftor 60 mg and 28 sachets ivacaftor 59.5 mg |  |  |\n| Trikafta\u24c7 |  |  |\n| VERTEX PHARMACEUTICALS (AUSTRALIA) PTY. LTD. (DUSC ana\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: a. |\n|---|------|---|\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| Syfovre\u00ae APELLIS AUSTRALIA PTY LTD |  | Authority Required (Written or Telephone/Online) initial treatment Authority Required (STREAMLINED) for continuing treatment |\n| (New PBS listing) PBS General Schedule |  |  |\n\n14\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA November 2025 PBAC MEETING\n\nClosing date for consumer comments 24 September 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submis\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nThe provided evidence does not contain the answer.\n...", "total_latency_sec": 4.369}
{"timestamp": "2025-07-31T10:35:59.709623Z", "query": "What is the dosage form of Apomorphine?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": false, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_clinical_data", "estimated_coverage": 0.7}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_clinical_data", "success": true, "content": "Evidence from document: e (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission, requested authority level (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| OMAVELOXOLONE Capsule 50 mg | Friedreich's ataxia | Resubmission to request listing of omavelo\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: tablets of elexacaftor 50 |  |  |\n| mg with tezacaftor 25 mg and ivacaftor 37.5 |  |  |\n| mg and 28 tablets of ivacaftor 75 mg |  |  |\n| Pack containing 28 sachets elexacaftor 100 mg with tezacaftor 50 mg and with ivacaftor |  |  |\n| 75 mg and 28 sachets ivacaftor 75 mg |  |  |\n| Pack containing 28 sachets elexacaftor 80 |  |  |\n| mg with tezacaftor 40 mg and with ivacaftor 60 mg and 28 sachets ivacaftor 59.5 mg |  |  |\n| Trikafta\u24c7 |  |  |\n| VERTEX PHARMACEUTICALS (AUSTRALIA) PTY. LTD. (DUSC ana\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| ELACESTRANT |  |  |\n| Tablet 86 mg (as dihydrochloride) Tablet 345 mg (as dihydrochloride) Orserdu\u24c7 A. MENARINI AUSTRALIA PTY LTD | Est\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: LINED) listing for the treatment of patients with extensive-stage small-cell lung cancer with disease progression after platinum-based chemotherapy and at least one other line of therapy (i.e. third- line therapy or thereafter). |\n|  |  |  |\n| WITHDRAWN |  |  |\n| TERIPARATIDE |  |  |\n| Injection 250 micrograms per mL, 2.4 mL in multi-dose pre-filled pen Ritosa\u24c7 SUN PHARMA ANZ PTY LTD (New PBS listing) | Osteoporosis | To request a General Schedule Authority Required (STREAMLINED) listing under t\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LTD | Advanced systemic mastocytosis | To request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for the treatment of adult patients with advanced systemic mastocytosis. |\n| (Change to existing listing) MOGAMULIZUMAB |  |  |\n| Solution concentrate for I.V. infusion 20 mg in 5 mL Poteligeo\u24c7 KYOWA KIRIN AUSTRALIA PTY LTD (New PBS listing) NATALIZUMAB | Cutaneous T-cell lymphoma (CTCL) | Resubmission to request a Section \nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: uested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| INFLIXIMAB Powder for I.V. infusion 100 mg Ixifi\u00ae PFIZER AUSTRALIA PTY LTD ( New PBS listing) | Severe active rheumatoid arthritis Ankylosing spondylitis Severe psoriatic arthritis Severe chronic plaque psoriasis | To request Section 100 (Highly Specialised Drugs Program) Authority Severe Crohn disease, Required listings of a new infliximab\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: COMMITTEE (PBAC) MEETING AGENDA\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) GEMCITABINE Solution for injection 1 g (as hydrochloride) in 25 mL Solution for injection 2 g (as hydrochloride) in 50 mL Gemcitabine Sandoz\u00ae SANDOZ PTY LTD (New PBS listing) INFLIXIMAB Solution for injection 120 mg in 1 mL pre- filled pen Soluti\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nThe provided evidence does not contain the answer.\n...", "total_latency_sec": 3.993}
{"timestamp": "2025-07-31T10:36:40.296832Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_general_text", "estimated_coverage": 0.6}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: ABALOPARATIDE hassponsor THERAMEX AUSTRALIA PTY LTD.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1-38)</a>", "estimated_coverage": 0.0}, {"tool_name": "retrieve_general_text", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe sponsor for Abaloparatide is Theramex Australia Pty Ltd. <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing...", "total_latency_sec": 9.436}
{"timestamp": "2025-07-31T10:36:55.951270Z", "query": "What is the trade name for Dostarlimab?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": false, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_clinical_data", "estimated_coverage": 0.7}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_clinical_data", "success": true, "content": "Evidence from document: nge to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| GUSELKUMAB |  |  |\n| Solution for I.V. infusion 200 mg in 20 mL vial Injection 100 mg in 1 mL single use pre-filled pen Injection 200 mg in 2 mL single use pre-filled pen, Injection 100 mg\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: s 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| ZOLBETUXIMAB |  |  |\n| Powder for I.V. in\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: AND PREDNISOLONE |  |  |\n| Pack containing 56 tablets abiraterone acetate 500 mg and 56 tablets prednisolone 5 mg Andriga-10 | Castration resistant metastatic carcinoma of the prostate (mCRPC) | To request a General Schedule Authority Required (Telephone/Online) listing of a composite pack containing abiraterone acetate and prednisolone for the treatment of patients with mCRPC. |\n| ACTOR PHARMACEUTICALS PTY LTD (New PBS listing) |  |  |\n| ACALABRUTINIB |  |  |\n| Tablet 100 mg Calquence\u00ae ASTRAZEN\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: COMMITTEE (PBAC) MEETING AGENDA\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) GEMCITABINE Solution for injection 1 g (as hydrochloride) in 25 mL Solution for injection 2 g (as hydrochloride) in 50 mL Gemcitabine Sandoz\u00ae SANDOZ PTY LTD (New PBS listing) INFLIXIMAB Solution for injection 120 mg in 1 mL pre- filled pen Soluti\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: e/high-risk primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis. |\n| Inrebic\u00ae |  | Authority Required (Telephone/Online) |\n| BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |  |  |\n| (New PBS listing) |  |  |\n| PBS General Schedule FENFLURAMINE Oral solution 2.2 mg (as hydrochloride) per mL, 360 mL | Lennox-Gastaut Syndrome (LGS) | To request listing of fenfluramine as add-on therapy for patients with LGS who are not adequately controlled with at\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: tablets of elexacaftor 50 |  |  |\n| mg with tezacaftor 25 mg and ivacaftor 37.5 |  |  |\n| mg and 28 tablets of ivacaftor 75 mg |  |  |\n| Pack containing 28 sachets elexacaftor 100 mg with tezacaftor 50 mg and with ivacaftor |  |  |\n| 75 mg and 28 sachets ivacaftor 75 mg |  |  |\n| Pack containing 28 sachets elexacaftor 80 |  |  |\n| mg with tezacaftor 40 mg and with ivacaftor 60 mg and 28 sachets ivacaftor 59.5 mg |  |  |\n| Trikafta\u24c7 |  |  |\n| VERTEX PHARMACEUTICALS (AUSTRALIA) PTY. LTD. (DUSC ana\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: a. |\n|---|------|---|\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| Syfovre\u00ae APELLIS AUSTRALIA PTY LTD |  | Authority Required (Written or Telephone/Online) initial treatment Authority Required (STREAMLINED) for continuing treatment |\n| (New PBS listing) PBS General Schedule |  |  |\n\n14\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA November 2025 PBAC MEETING\n\nClosing date for consumer comments 24 September 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submis\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nThe provided evidence does not contain the answer.\n...", "total_latency_sec": 5.844}
{"timestamp": "2025-07-31T10:37:09.139812Z", "query": "What is the dosage form of Apomorphine?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": false, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_clinical_data", "estimated_coverage": 0.7}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_clinical_data", "success": true, "content": "Evidence from document: e (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission, requested authority level (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| OMAVELOXOLONE Capsule 50 mg | Friedreich's ataxia | Resubmission to request listing of omavelo\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: tablets of elexacaftor 50 |  |  |\n| mg with tezacaftor 25 mg and ivacaftor 37.5 |  |  |\n| mg and 28 tablets of ivacaftor 75 mg |  |  |\n| Pack containing 28 sachets elexacaftor 100 mg with tezacaftor 50 mg and with ivacaftor |  |  |\n| 75 mg and 28 sachets ivacaftor 75 mg |  |  |\n| Pack containing 28 sachets elexacaftor 80 |  |  |\n| mg with tezacaftor 40 mg and with ivacaftor 60 mg and 28 sachets ivacaftor 59.5 mg |  |  |\n| Trikafta\u24c7 |  |  |\n| VERTEX PHARMACEUTICALS (AUSTRALIA) PTY. LTD. (DUSC ana\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| ELACESTRANT |  |  |\n| Tablet 86 mg (as dihydrochloride) Tablet 345 mg (as dihydrochloride) Orserdu\u24c7 A. MENARINI AUSTRALIA PTY LTD | Est\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: LINED) listing for the treatment of patients with extensive-stage small-cell lung cancer with disease progression after platinum-based chemotherapy and at least one other line of therapy (i.e. third- line therapy or thereafter). |\n|  |  |  |\n| WITHDRAWN |  |  |\n| TERIPARATIDE |  |  |\n| Injection 250 micrograms per mL, 2.4 mL in multi-dose pre-filled pen Ritosa\u24c7 SUN PHARMA ANZ PTY LTD (New PBS listing) | Osteoporosis | To request a General Schedule Authority Required (STREAMLINED) listing under t\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LTD | Advanced systemic mastocytosis | To request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for the treatment of adult patients with advanced systemic mastocytosis. |\n| (Change to existing listing) MOGAMULIZUMAB |  |  |\n| Solution concentrate for I.V. infusion 20 mg in 5 mL Poteligeo\u24c7 KYOWA KIRIN AUSTRALIA PTY LTD (New PBS listing) NATALIZUMAB | Cutaneous T-cell lymphoma (CTCL) | Resubmission to request a Section \nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: uested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| INFLIXIMAB Powder for I.V. infusion 100 mg Ixifi\u00ae PFIZER AUSTRALIA PTY LTD ( New PBS listing) | Severe active rheumatoid arthritis Ankylosing spondylitis Severe psoriatic arthritis Severe chronic plaque psoriasis | To request Section 100 (Highly Specialised Drugs Program) Authority Severe Crohn disease, Required listings of a new infliximab\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: COMMITTEE (PBAC) MEETING AGENDA\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) GEMCITABINE Solution for injection 1 g (as hydrochloride) in 25 mL Solution for injection 2 g (as hydrochloride) in 50 mL Gemcitabine Sandoz\u00ae SANDOZ PTY LTD (New PBS listing) INFLIXIMAB Solution for injection 120 mg in 1 mL pre- filled pen Soluti\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nThe provided evidence does not contain the answer.\n...", "total_latency_sec": 5.268}
{"timestamp": "2025-07-31T10:55:29.333343Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_general_text", "estimated_coverage": 0.6}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: ABALOPARATIDE hassponsor THERAMEX AUSTRALIA PTY LTD.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1-38)</a>", "estimated_coverage": 0.0}, {"tool_name": "retrieve_general_text", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe sponsor for Abaloparatide is Theramex Australia Pty Ltd. <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing...", "total_latency_sec": 6.585}
{"timestamp": "2025-07-31T10:55:37.834159Z", "query": "What is Amivantamab used to treat?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_clinical_data", "estimated_coverage": 0.7}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: AMIVANTAMAB hasindication Non-small cell lung cancer (NSCLC).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1-30)</a>", "estimated_coverage": 0.0}, {"tool_name": "retrieve_clinical_data", "success": true, "content": "Evidence from document: ug Name, form(s), strength(s) and Sponsor, Submission type, PBS schedule (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission, requested authority level (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| DURVALUMAB Solution con\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: (Highly Specialised Drugs Program) |  |  |\n\n22\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA November 2025 PBAC MEETING\n\nClosing date for consumer comments 24 September 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type, PBS schedule (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission, requested authority level (Includes t\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: e/high-risk primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis. |\n| Inrebic\u00ae |  | Authority Required (Telephone/Online) |\n| BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |  |  |\n| (New PBS listing) |  |  |\n| PBS General Schedule FENFLURAMINE Oral solution 2.2 mg (as hydrochloride) per mL, 360 mL | Lennox-Gastaut Syndrome (LGS) | To request listing of fenfluramine as add-on therapy for patients with LGS who are not adequately controlled with at\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: uested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| INFLIXIMAB Powder for I.V. infusion 100 mg Ixifi\u00ae PFIZER AUSTRALIA PTY LTD ( New PBS listing) | Severe active rheumatoid arthritis Ankylosing spondylitis Severe psoriatic arthritis Severe chronic plaque psoriasis | To request Section 100 (Highly Specialised Drugs Program) Authority Severe Crohn disease, Required listings of a new infliximab\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: a. |\n|---|------|---|\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| Syfovre\u00ae APELLIS AUSTRALIA PTY LTD |  | Authority Required (Written or Telephone/Online) initial treatment Authority Required (STREAMLINED) for continuing treatment |\n| (New PBS listing) PBS General Schedule |  |  |\n\n14\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA November 2025 PBAC MEETING\n\nClosing date for consumer comments 24 September 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submis\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: |  |  |\n\n13\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA May 2025 PBAC MEETING\n\nClosing date for consumer comments 26 March 2025\n\n| Review of antiepileptic drugs (AEDs) |  |  |\n|---|------|---|\n| Multiple Forms Multiple Brands Multiple Sponsors | Epilepsy | To consider amending the current PBS listings for the second-line AEDs, levetiracetam (LEV) and lamotrigine (LTG), to allow their first-line use in the general Australian population with epilepsy. |\n| (PBS review) Review \nCitation: <a href=\"#\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| ELACESTRANT |  |  |\n| Tablet 86 mg (as dihydrochloride) Tablet 345 mg (as dihydrochloride) Orserdu\u24c7 A. MENARINI AUSTRALIA PTY LTD | Est\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nAmivantamab is used to treat Non-small cell lung cancer (NSCLC). <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/...", "total_latency_sec": 5.155}
{"timestamp": "2025-07-31T10:55:46.048196Z", "query": "What is the trade name for Dostarlimab?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": false, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_clinical_data", "estimated_coverage": 0.7}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_clinical_data", "success": true, "content": "Evidence from document: nge to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| GUSELKUMAB |  |  |\n| Solution for I.V. infusion 200 mg in 20 mL vial Injection 100 mg in 1 mL single use pre-filled pen Injection 200 mg in 2 mL single use pre-filled pen, Injection 100 mg\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: s 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| ZOLBETUXIMAB |  |  |\n| Powder for I.V. in\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: AND PREDNISOLONE |  |  |\n| Pack containing 56 tablets abiraterone acetate 500 mg and 56 tablets prednisolone 5 mg Andriga-10 | Castration resistant metastatic carcinoma of the prostate (mCRPC) | To request a General Schedule Authority Required (Telephone/Online) listing of a composite pack containing abiraterone acetate and prednisolone for the treatment of patients with mCRPC. |\n| ACTOR PHARMACEUTICALS PTY LTD (New PBS listing) |  |  |\n| ACALABRUTINIB |  |  |\n| Tablet 100 mg Calquence\u00ae ASTRAZEN\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: COMMITTEE (PBAC) MEETING AGENDA\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) GEMCITABINE Solution for injection 1 g (as hydrochloride) in 25 mL Solution for injection 2 g (as hydrochloride) in 50 mL Gemcitabine Sandoz\u00ae SANDOZ PTY LTD (New PBS listing) INFLIXIMAB Solution for injection 120 mg in 1 mL pre- filled pen Soluti\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: e/high-risk primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis. |\n| Inrebic\u00ae |  | Authority Required (Telephone/Online) |\n| BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |  |  |\n| (New PBS listing) |  |  |\n| PBS General Schedule FENFLURAMINE Oral solution 2.2 mg (as hydrochloride) per mL, 360 mL | Lennox-Gastaut Syndrome (LGS) | To request listing of fenfluramine as add-on therapy for patients with LGS who are not adequately controlled with at\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: tablets of elexacaftor 50 |  |  |\n| mg with tezacaftor 25 mg and ivacaftor 37.5 |  |  |\n| mg and 28 tablets of ivacaftor 75 mg |  |  |\n| Pack containing 28 sachets elexacaftor 100 mg with tezacaftor 50 mg and with ivacaftor |  |  |\n| 75 mg and 28 sachets ivacaftor 75 mg |  |  |\n| Pack containing 28 sachets elexacaftor 80 |  |  |\n| mg with tezacaftor 40 mg and with ivacaftor 60 mg and 28 sachets ivacaftor 59.5 mg |  |  |\n| Trikafta\u24c7 |  |  |\n| VERTEX PHARMACEUTICALS (AUSTRALIA) PTY. LTD. (DUSC ana\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: a. |\n|---|------|---|\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| Syfovre\u00ae APELLIS AUSTRALIA PTY LTD |  | Authority Required (Written or Telephone/Online) initial treatment Authority Required (STREAMLINED) for continuing treatment |\n| (New PBS listing) PBS General Schedule |  |  |\n\n14\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA November 2025 PBAC MEETING\n\nClosing date for consumer comments 24 September 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submis\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nThe provided evidence does not contain the answer.\n...", "total_latency_sec": 3.689}
{"timestamp": "2025-07-31T10:55:53.241072Z", "query": "What is the dosage form of Apomorphine?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": false, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_clinical_data", "estimated_coverage": 0.7}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_clinical_data", "success": true, "content": "Evidence from document: e (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission, requested authority level (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| OMAVELOXOLONE Capsule 50 mg | Friedreich's ataxia | Resubmission to request listing of omavelo\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: tablets of elexacaftor 50 |  |  |\n| mg with tezacaftor 25 mg and ivacaftor 37.5 |  |  |\n| mg and 28 tablets of ivacaftor 75 mg |  |  |\n| Pack containing 28 sachets elexacaftor 100 mg with tezacaftor 50 mg and with ivacaftor |  |  |\n| 75 mg and 28 sachets ivacaftor 75 mg |  |  |\n| Pack containing 28 sachets elexacaftor 80 |  |  |\n| mg with tezacaftor 40 mg and with ivacaftor 60 mg and 28 sachets ivacaftor 59.5 mg |  |  |\n| Trikafta\u24c7 |  |  |\n| VERTEX PHARMACEUTICALS (AUSTRALIA) PTY. LTD. (DUSC ana\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| ELACESTRANT |  |  |\n| Tablet 86 mg (as dihydrochloride) Tablet 345 mg (as dihydrochloride) Orserdu\u24c7 A. MENARINI AUSTRALIA PTY LTD | Est\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: LINED) listing for the treatment of patients with extensive-stage small-cell lung cancer with disease progression after platinum-based chemotherapy and at least one other line of therapy (i.e. third- line therapy or thereafter). |\n|  |  |  |\n| WITHDRAWN |  |  |\n| TERIPARATIDE |  |  |\n| Injection 250 micrograms per mL, 2.4 mL in multi-dose pre-filled pen Ritosa\u24c7 SUN PHARMA ANZ PTY LTD (New PBS listing) | Osteoporosis | To request a General Schedule Authority Required (STREAMLINED) listing under t\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LTD | Advanced systemic mastocytosis | To request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for the treatment of adult patients with advanced systemic mastocytosis. |\n| (Change to existing listing) MOGAMULIZUMAB |  |  |\n| Solution concentrate for I.V. infusion 20 mg in 5 mL Poteligeo\u24c7 KYOWA KIRIN AUSTRALIA PTY LTD (New PBS listing) NATALIZUMAB | Cutaneous T-cell lymphoma (CTCL) | Resubmission to request a Section \nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: uested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| INFLIXIMAB Powder for I.V. infusion 100 mg Ixifi\u00ae PFIZER AUSTRALIA PTY LTD ( New PBS listing) | Severe active rheumatoid arthritis Ankylosing spondylitis Severe psoriatic arthritis Severe chronic plaque psoriasis | To request Section 100 (Highly Specialised Drugs Program) Authority Severe Crohn disease, Required listings of a new infliximab\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: COMMITTEE (PBAC) MEETING AGENDA\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) GEMCITABINE Solution for injection 1 g (as hydrochloride) in 25 mL Solution for injection 2 g (as hydrochloride) in 50 mL Gemcitabine Sandoz\u00ae SANDOZ PTY LTD (New PBS listing) INFLIXIMAB Solution for injection 120 mg in 1 mL pre- filled pen Soluti\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nThe provided evidence does not contain the answer.\n...", "total_latency_sec": 3.593}
{"timestamp": "2025-07-31T10:56:16.531409Z", "query": "What is the dosage form of Apomorphine?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": false, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_clinical_data", "estimated_coverage": 0.7}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_clinical_data", "success": true, "content": "Evidence from document: e (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission, requested authority level (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| OMAVELOXOLONE Capsule 50 mg | Friedreich's ataxia | Resubmission to request listing of omavelo\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: tablets of elexacaftor 50 |  |  |\n| mg with tezacaftor 25 mg and ivacaftor 37.5 |  |  |\n| mg and 28 tablets of ivacaftor 75 mg |  |  |\n| Pack containing 28 sachets elexacaftor 100 mg with tezacaftor 50 mg and with ivacaftor |  |  |\n| 75 mg and 28 sachets ivacaftor 75 mg |  |  |\n| Pack containing 28 sachets elexacaftor 80 |  |  |\n| mg with tezacaftor 40 mg and with ivacaftor 60 mg and 28 sachets ivacaftor 59.5 mg |  |  |\n| Trikafta\u24c7 |  |  |\n| VERTEX PHARMACEUTICALS (AUSTRALIA) PTY. LTD. (DUSC ana\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| ELACESTRANT |  |  |\n| Tablet 86 mg (as dihydrochloride) Tablet 345 mg (as dihydrochloride) Orserdu\u24c7 A. MENARINI AUSTRALIA PTY LTD | Est\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: LINED) listing for the treatment of patients with extensive-stage small-cell lung cancer with disease progression after platinum-based chemotherapy and at least one other line of therapy (i.e. third- line therapy or thereafter). |\n|  |  |  |\n| WITHDRAWN |  |  |\n| TERIPARATIDE |  |  |\n| Injection 250 micrograms per mL, 2.4 mL in multi-dose pre-filled pen Ritosa\u24c7 SUN PHARMA ANZ PTY LTD (New PBS listing) | Osteoporosis | To request a General Schedule Authority Required (STREAMLINED) listing under t\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LTD | Advanced systemic mastocytosis | To request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for the treatment of adult patients with advanced systemic mastocytosis. |\n| (Change to existing listing) MOGAMULIZUMAB |  |  |\n| Solution concentrate for I.V. infusion 20 mg in 5 mL Poteligeo\u24c7 KYOWA KIRIN AUSTRALIA PTY LTD (New PBS listing) NATALIZUMAB | Cutaneous T-cell lymphoma (CTCL) | Resubmission to request a Section \nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: uested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| INFLIXIMAB Powder for I.V. infusion 100 mg Ixifi\u00ae PFIZER AUSTRALIA PTY LTD ( New PBS listing) | Severe active rheumatoid arthritis Ankylosing spondylitis Severe psoriatic arthritis Severe chronic plaque psoriasis | To request Section 100 (Highly Specialised Drugs Program) Authority Severe Crohn disease, Required listings of a new infliximab\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: COMMITTEE (PBAC) MEETING AGENDA\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) GEMCITABINE Solution for injection 1 g (as hydrochloride) in 25 mL Solution for injection 2 g (as hydrochloride) in 50 mL Gemcitabine Sandoz\u00ae SANDOZ PTY LTD (New PBS listing) INFLIXIMAB Solution for injection 120 mg in 1 mL pre- filled pen Soluti\nCitation: <a href=\"#\" target=\"_blank\">March-2025-PBAC-Meeting (Page N/A)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nThe provided evidence does not contain the answer.\n...", "total_latency_sec": 6.452}
{"timestamp": "2025-07-31T10:56:25.204807Z", "query": "Provide a summary of the key submissions from the May 2025 PBAC meeting.", "persona": "automatic", "intent": "simple_summary", "graph_suitable": false, "tool_plan": [{"tool_name": "retrieve_general_text", "estimated_coverage": 0.8}, {"tool_name": "retrieve_summary_data", "estimated_coverage": 0.72}], "tool_results": [{"tool_name": "retrieve_general_text", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_summary_data", "success": true, "content": "Evidence from document: The table presents the agenda for the November 2025 PBAC meeting, including submissions for changes to existing listings and new listings for National Immunisation Program (NIP) inclusion.  GlaxoSmithKline Australia Pty Ltd requests a change to the existing NIP listing for Shingrix\u00ae, a recombinant zoster vaccine, to lower the eligible age for non-Indigenous adults from 65 to 60 years. Moderna Australia Pty Ltd seeks a new NIP listing for mResvia\u00ae, a respiratory syncytial virus (RSV) vaccine, for\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: The May 2025 PBAC meeting agenda includes items related to a new listing request for RRMS treatment by Kirchmann Enterprises, review of ATAGI recommendations on pediatric pneumococcal schedule, utilization assessment of fluticasone furoate + umeclidinium + vilanterol for severe asthma, utilization review of medicines for gastrointestinal stromal tumour, and utilization review of zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia.\nCitation: <a href=\"#\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: The July 2025 PBAC meeting agenda includes Abaloparatide for the first-line treatment of severe established osteoporosis under a General Schedule Authority Required listing and Abiraterone Acetate, with further details to be provided in the subsequent table rows.\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Ph\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: The table presents an agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the Pharmaceutical Benefits Scheme (PBS). Submissions include Brexpiprazole for schizophrenia, Bulevirtide for chronic hepatitis D (resubmission), and Cabozantinib for pancreatic and extra-pancreatic neuroendocrine tumors. The closing date for consumer comments was May 28, 2025.\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe May 2025 PBAC meeting included: a new listing request for RRMS treatment by Kirchmann Enterprises; review of ATAGI recommendations on ...", "total_latency_sec": 5.343}
{"timestamp": "2025-07-31T10:56:33.533104Z", "query": "Summarize all submissions related to oncology in the March 2025 documents.", "persona": "automatic", "intent": "simple_summary", "graph_suitable": false, "tool_plan": [{"tool_name": "retrieve_general_text", "estimated_coverage": 0.8}, {"tool_name": "retrieve_summary_data", "estimated_coverage": 0.72}], "tool_results": [{"tool_name": "retrieve_general_text", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_summary_data", "success": true, "content": "Evidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: The May 2025 PBAC meeting agenda includes items related to a new listing request for RRMS treatment by Kirchmann Enterprises, review of ATAGI recommendations on pediatric pneumococcal schedule, utilization assessment of fluticasone furoate + umeclidinium + vilanterol for severe asthma, utilization review of medicines for gastrointestinal stromal tumour, and utilization review of zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia.\nCitation: <a href=\"#\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: The table presents the agenda for the November 2025 PBAC meeting, including submissions for changes to existing listings and new listings for National Immunisation Program (NIP) inclusion.  GlaxoSmithKline Australia Pty Ltd requests a change to the existing NIP listing for Shingrix\u00ae, a recombinant zoster vaccine, to lower the eligible age for non-Indigenous adults from 65 to 60 years. Moderna Australia Pty Ltd seeks a new NIP listing for mResvia\u00ae, a respiratory syncytial virus (RSV) vaccine, for\nCitation: <a href=\"#\" target=\"_blank\">November-2025-PBAC-Meeting (Page N/A)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, including consumer comment deadlines and details of drug submissions.  It includes requests for changes to existing listings (e.g., Ranibizumab for proliferative diabetic retinopathy) and new listings (e.g., Raxtozinameran for COVID-19 prevention in specific adult populations).\nCitation: <a href=\"#\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"#\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Ph\nCitation: <a href=\"#\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page N/A)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe provided evidence does not contain the answer.\n...", "total_latency_sec": 4.687}
{"timestamp": "2025-07-31T11:01:02.538948Z", "query": "What is the trade name for Dostarlimab?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": false, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_clinical_data", "estimated_coverage": 0.7}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_clinical_data", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nI searched but could not find any relevant details for this step....", "total_latency_sec": 5.95}
{"timestamp": "2025-07-31T11:01:09.009890Z", "query": "What is the dosage form of Apomorphine?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": false, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_clinical_data", "estimated_coverage": 0.7}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_clinical_data", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nI searched but could not find any relevant details for this step....", "total_latency_sec": 3.377}
{"timestamp": "2025-07-31T11:01:16.681758Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_general_text", "estimated_coverage": 0.6}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: ABALOPARATIDE hassponsor THERAMEX AUSTRALIA PTY LTD.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1-38)</a>", "estimated_coverage": 0.0}, {"tool_name": "retrieve_general_text", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe sponsor for Abaloparatide is Theramex Australia Pty Ltd. <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing...", "total_latency_sec": 6.208}
{"timestamp": "2025-07-31T11:58:49.294407Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_general_text", "estimated_coverage": 0.6}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: ABALOPARATIDE hassponsor THERAMEX AUSTRALIA PTY LTD.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1-38)</a>", "estimated_coverage": 0.0}, {"tool_name": "retrieve_general_text", "success": true, "content": "Evidence from document: RIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Submission type amended\n\n30. TRIGLYCERIDES - MEDIUM CHAIN, FORMULA (Monogen\u00ae) \u2013 Added\n\n38\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=3\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 3, 30, 38, 8)</a>\n---\nEvidence from document: The table presents the agenda for the March 2025 PBAC meeting, detailing new drug submissions and listing requests.  It includes drugs like Dupilumab (Dupixent\u00ae) for atopic dermatitis and asthma in children, Efgartigimod alfa (Vyvgart\u00ae) for myasthenia gravis, and Eflornithine (Ifinwil\u00ae) for neuroblastoma.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, ...)</a>\n---\nEvidence from document: This table details new drug submissions for the November 2025 PBAC meeting.  Tezepelumab (Tezspire\u00ae) is submitted by AstraZeneca Pty Ltd for severe uncontrolled asthma in patients 12+ years old. Tocilizumab (Avtozma\u00ae), a biosimilar, is submitted by Celltrion Healthcare Australia Pty Ltd for various indications mirroring the originator brand.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, ...)</a>\n---\nEvidence from document: This table presents an agenda for the November 2025 PBAC meeting, including submissions for Osimertinib and Pegcetacoplan.  AstraZeneca seeks an expanded listing for Osimertinib for first-line treatment of EGFRm NSCLC in combination with chemotherapy.  A listing is requested for Pegcetacoplan for treating bilateral GA secondary to AMD in eyes with an intact fovea and threatened central vision.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, ...)</a>\n---\nEvidence from document: iasis, and juvenile idiopathic arthritis. Resubmission to request a General Schedule Authority Required (STREAMLINED) listing for the treatment of patients with locally advanced or metastatic cholangiocarcinoma who have previously progressed on systemic therapy and have a fibroblast growth factor receptor 2 fusion or rearrangement. |\n\n10\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nJuly 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| GIVOSIRAN |  |  |\n| Solution for injection 189 mg in 1 mL Givlaari\u24c7 MEDISON PHARMA AUSTRALIA PTY LIMITED | Acute hepatic porphyria (AHP) | To request a General Schedule Authority Required (Written) listing for the initial treatment and an Authority Required (STREAMLINED) listing for the continuing treatment of AHP in adults and adolescents aged 12 years and older. |\n| (New PBS listing) GLOFITAMAB |  |  |\n| Solution concentrate for I.V. infusion 2.5 mg in 2.5 mL Solution concentrate for I.V. infusion 10 mg in 10 mL Columvi\u24c7 | Relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL) | To request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (Telephone/Online) listing for the treatment of patients with RR DLBCL. |\n| ROCHE PRODUCTS PTY LTD (New PBS listing) |  |  |\n\n11\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nJuly 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/cha\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, ...)</a>\n---\nEvidence from document: The table shows drug submissions for the March 2025 PBAC meeting, including new listings and listing changes. It details the drug name, usage, and the sponsor's requested listing type (unrestricted, restricted benefit, or authority required). Drugs mentioned include Infliximab, Ivacaftor, Lumasiran, and Midostaurin.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, ...)</a>\n---\nEvidence from document: The table presents the agenda for the November 2025 PBAC meeting, detailing submissions for Acalabrutinib and Aflibercept for new indications and a biosimilar listing, respectively.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, ...)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe sponsor for Abaloparatide is THERAMEX AUSTRALIA PTY LTD. <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing...", "total_latency_sec": 6.907}
{"timestamp": "2025-07-31T11:59:09.457849Z", "query": "What is Amivantamab used to treat?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": false, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_clinical_data", "estimated_coverage": 0.7}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_clinical_data", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nI searched but could not find any relevant details for this step....", "total_latency_sec": 2.875}
{"timestamp": "2025-07-31T11:59:18.893004Z", "query": "What is the trade name for Dostarlimab?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": false, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "retrieve_clinical_data", "estimated_coverage": 0.7}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "retrieve_clinical_data", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nI searched but could not find any relevant details for this step....", "total_latency_sec": 3.297}
{"timestamp": "2025-07-31T12:06:01.560317Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "classification_failed", "graph_suitable": "unknown", "tool_plan": [], "tool_results": [], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nI had trouble understanding the query....", "total_latency_sec": 2.516}
{"timestamp": "2025-07-31T12:06:10.083227Z", "query": "What is Amivantamab used to treat?", "persona": "automatic", "intent": "classification_failed", "graph_suitable": "unknown", "tool_plan": [], "tool_results": [], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nI had trouble understanding the query....", "total_latency_sec": 1.651}
{"timestamp": "2025-07-31T12:09:02.358862Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: ABALOPARATIDE hassponsor THERAMEX AUSTRALIA PTY LTD.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1-38\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1-38)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table details submissions for the July 2025 PBAC meeting, specifically focusing on reviews of positive PBAC recommendations not yet accepted by applicants.  It includes Galcanezumab for treatment-resistant high frequency episodic migraine, Hyaluronic Acid with Polyethylene Glycol 400 with Propylene Glycol with Hydroxypropyl Guar for severe dry eye syndrome, Mirikizumab for ulcerative colitis, and Mobocertinib.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table details new drug submissions for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC) for the November 2025 meeting. Submissions include retifanlimab (Zynyz\u00ae) by Specialised Therapeutics for Merkel cell carcinoma and squamous cell anal carcinoma, and risdiplam (Evrysdi\u00ae) by Roche for spinal muscular atrophy.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 2, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 2, 20, 22, 25, 28, 3, 37, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table from the November 2025 PBAC Meeting agenda details several drug submissions, including zanubrutinib for MCL, WM, CLL, and SLL; daratumumab for AL amyloidosis in combination with other drugs; and elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta\u00ae) for cystic fibrosis. The submissions aim to either list new drug forms or assess the utilization of existing PBS-listed medications for these conditions.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe sponsor for Abaloparatide is Theramex Australia Pty Ltd. <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing...", "total_latency_sec": 7.597}
{"timestamp": "2025-07-31T12:09:17.937971Z", "query": "What is Amivantamab used to treat?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: AMIVANTAMAB hasindication Non-small cell lung cancer (NSCLC).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1-30\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1-30)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nAmivantamab is used to treat Non-small cell lung cancer (NSCLC). <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/...", "total_latency_sec": 5.658}
{"timestamp": "2025-07-31T12:09:25.213594Z", "query": "What is the trade name for Dostarlimab?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: DOSTARLIMAB hastradename Jemperli\u00ae.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1-14\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page 1-14)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: This table presents the agenda for the November 2025 PBAC meeting, detailing drug submissions for new PBS listings or changes to existing listings.  It includes Spesolimab for generalized pustular psoriasis flares, Tafasitamab for relapsed and/or refractory follicular lymphoma, and Testosterone for hypoactive sexual desire dysfunction in postmenopausal women.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the July 2025 PBAC meeting, focusing on Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) and a request for a Section 100 listing for APDS.  It details several drugs (Eliglustat, Imiglucerase, Taliglucerase Alfa, Velaglucerase Alfa) and their submission types for PBS listing consideration.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents the agenda for the March 2025 PBAC meeting, detailing drug submissions, including new listings and changes to existing listings.  It includes ZOLBETUXIMAB for gastric or gastroesophageal junction cancer and ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR for cystic fibrosis.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents the agenda for the March 2025 PBAC meeting, detailing new drug submissions and listing requests.  It includes drugs like Dupilumab (Dupixent\u00ae) for atopic dermatitis and asthma in children, Efgartigimod alfa (Vyvgart\u00ae) for myasthenia gravis, and Eflornithine (Ifinwil\u00ae) for neuroblastoma.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents the agenda for the May 2025 PBAC meeting, detailing submissions for new or amended listings of Repotrectinib, Teprotumumab, and Trastuzumab Deruxtecan for various cancer and thyroid eye disease indications. The meeting also includes a submission for Ublituximab for relapsing-remitting multiple sclerosis.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 2, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: ral Schedule Authority Required listings of two aflibercept biosimilars for the treatment of RVO, DMO, and CNV due to AMD under the same conditions as their respective reference biologic.  To request General Schedule Authority Required (STREAMLINED) and Section 100 (Highly Specialised Drugs Program) Authority Required (STREAMLINED) listings of Movapo\u00ae POD, administered via an infusion pump with a collar attachment, under the existing listings for Apomine Solution for Infusion for the treatment of Parkinson's disease. |\n|  |  |  |\n| (New PBS listing) |  |  |\n\n4\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nJuly 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| ARIPIPRAZOLE |  |  |\n| Powder for injection 300 mg (as monohydrate) with diluent in pre-filled dual- chamber syringe Powder for injection 400 mg (as monohydrate) with diluent in pre-filled dual- chamber syringe Abilify Maintena\u00ae LUNDBECK AUSTRALIA PTY LTD (New PBS listing) BRENTUXIMAB VEDOTIN Powder for I.V. infusion 50 mg Adcetris\u00ae TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD. (Change to existing listing) | Schizophrenia   Hodgkin lymphoma | To request General Schedule Authority Required (STREAMLINED) listings of two new forms for the treatment of schizophrenia.   Resubmission to request a Section 100 (Efficient Funding of Chemotherapy) Authority Required (Written) listing for the first line treatment of advanced Hodgkin lymphoma in combination with chemotherapy. |\n\n5\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nJuly 2025\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents a list of drugs being considered for listing or changes to existing listings, including Elacestrant for breast cancer, Elafibranor for PBC, and Elexacaftor/Tezacaftor/Ivacaftor for cystic fibrosis. Each entry includes the drug's form, strength, trade name, sponsor, and the specific listing requested by the sponsor.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the November 2025 PBAC meeting, detailing drug submissions, including Durvalumab for muscle invasive bladder cancer and Efgartigimod alfa for generalized myasthenia gravis.  The submissions specify the requested listing type and authority level.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the November 2025 PBAC meeting, detailing new drug submissions and listing requests for encorafenib, binimetinib, estradiol with progesterone, and fedratinib for various indications like NSCLC, vasomotor symptoms, and myelofibrosis.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: Novo Nordisk Pharmaceuticals Pty. Ltd. has resubmitted a request to list Semaglutide (Wegovy\u00ae) on the PBS General Schedule for the treatment of patients with established cardiovascular disease (eCVD) and overweight or obesity.  The submission seeks Authority Required (Telephone/Online) listing status.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nThe trade name for Dostarlimab is Jemperli\u00ae. <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetin...", "total_latency_sec": 5.517}
{"timestamp": "2025-07-31T12:09:36.912980Z", "query": "What is the dosage form of Apomorphine?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: Apomorphine hasdosageform Injection containing apomorphine hydrochloride hemihydrate 100 mg.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1-38\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1-38)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table details various dosage forms and combinations of Elexacaftor, Tezacaftor, and Ivacaftor, including tablets and sachets with different strengths of each component, packaged together for administration under the trade name Trikafta\u00ae by Vertex Pharmaceuticals (Australia) Pty. Ltd.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 2, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nApomorphine has a dosage form of Injection containing apomorphine hydrochloride hemihydrate 100 mg. <a href=\"https://storage.googleapis.com/fre...", "total_latency_sec": 5.5}
{"timestamp": "2025-07-31T12:09:53.414254Z", "query": "Which sponsors made submissions in both the March 2025 and July 2025 meetings?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 2, 20, 22, 25, 28, 3, 37, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 2, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table details submissions for the July 2025 PBAC meeting, specifically focusing on reviews of positive PBAC recommendations not yet accepted by applicants.  It includes Galcanezumab for treatment-resistant high frequency episodic migraine, Hyaluronic Acid with Polyethylene Glycol 400 with Propylene Glycol with Hydroxypropyl Guar for severe dry eye syndrome, Mirikizumab for ulcerative colitis, and Mobocertinib.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Pharmaceuticals Pty. Ltd. for paediatric patients with growth hormone deficiency. One submission was withdrawn.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe provided evidence does not contain the answer.\n...", "total_latency_sec": 5.946}
{"timestamp": "2025-07-31T12:10:02.213277Z", "query": "Compare the submission purposes for Acalabrutinib and Alectinib in the 2025 meetings.", "persona": "automatic", "intent": "comparison", "graph_suitable": false, "tool_plan": [{"tool_name": "vector_search", "estimated_coverage": 0.5}, {"tool_name": "query_knowledge_graph", "estimated_coverage": 0.45}], "tool_results": [{"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 2, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Pharmaceuticals Pty. Ltd. for paediatric patients with growth hormone deficiency. One submission was withdrawn.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table from the November 2025 PBAC Meeting agenda details several drug submissions, including zanubrutinib for MCL, WM, CLL, and SLL; daratumumab for AL amyloidosis in combination with other drugs; and elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta\u00ae) for cystic fibrosis. The submissions aim to either list new drug forms or assess the utilization of existing PBS-listed medications for these conditions.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table details submissions for the July 2025 PBAC meeting, specifically focusing on reviews of positive PBAC recommendations not yet accepted by applicants.  It includes Galcanezumab for treatment-resistant high frequency episodic migraine, Hyaluronic Acid with Polyethylene Glycol 400 with Propylene Glycol with Hydroxypropyl Guar for severe dry eye syndrome, Mirikizumab for ulcerative colitis, and Mobocertinib.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table details several drug submissions for the November 2025 PBAC meeting, including requests for new listings (Zanubrutinib for various blood cancers) and changes to existing listings (Vedolizumab for Crohn's disease and ulcerative colitis, and Renastart for chronic renal failure).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>", "estimated_coverage": 0.0}, {"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nI found some information, but it did not seem relevant to your question....", "total_latency_sec": 3.429}
{"timestamp": "2025-07-31T12:10:07.898046Z", "query": "Compare the submission purposes for Acalabrutinib and Alectinib in the 2025 meetings.", "persona": "automatic", "intent": "comparison", "graph_suitable": false, "tool_plan": [{"tool_name": "vector_search", "estimated_coverage": 0.5}, {"tool_name": "query_knowledge_graph", "estimated_coverage": 0.45}], "tool_results": [{"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 2, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Pharmaceuticals Pty. Ltd. for paediatric patients with growth hormone deficiency. One submission was withdrawn.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table from the November 2025 PBAC Meeting agenda details several drug submissions, including zanubrutinib for MCL, WM, CLL, and SLL; daratumumab for AL amyloidosis in combination with other drugs; and elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta\u00ae) for cystic fibrosis. The submissions aim to either list new drug forms or assess the utilization of existing PBS-listed medications for these conditions.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table details submissions for the July 2025 PBAC meeting, specifically focusing on reviews of positive PBAC recommendations not yet accepted by applicants.  It includes Galcanezumab for treatment-resistant high frequency episodic migraine, Hyaluronic Acid with Polyethylene Glycol 400 with Propylene Glycol with Hydroxypropyl Guar for severe dry eye syndrome, Mirikizumab for ulcerative colitis, and Mobocertinib.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table details several drug submissions for the November 2025 PBAC meeting, including requests for new listings (Zanubrutinib for various blood cancers) and changes to existing listings (Vedolizumab for Crohn's disease and ulcerative colitis, and Renastart for chronic renal failure).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>", "estimated_coverage": 0.0}, {"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nI found some information, but it did not seem relevant to your question....", "total_latency_sec": 4.181}
{"timestamp": "2025-07-31T12:10:09.317632Z", "query": "What is the indication for the drug whose trade name is Cabometyx?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nI searched but could not find any relevant details....", "total_latency_sec": 4.389}
{"timestamp": "2025-07-31T12:10:14.567869Z", "query": "Provide a summary of the key submissions from the May 2025 PBAC meeting.", "persona": "automatic", "intent": "simple_summary", "graph_suitable": false, "tool_plan": [{"tool_name": "vector_search", "estimated_coverage": 0.5}, {"tool_name": "query_knowledge_graph", "estimated_coverage": 0.36}], "tool_results": [{"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Pharmaceuticals Pty. Ltd. for paediatric patients with growth hormone deficiency. One submission was withdrawn.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the Pharmaceutical Benefits Scheme (PBS). Submissions include Brexpiprazole for schizophrenia, Bulevirtide for chronic hepatitis D (resubmission), and Cabozantinib for pancreatic and extra-pancreatic neuroendocrine tumors. The closing date for consumer comments was May 28, 2025.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 2, 20, 22, 25, 28, 3, 37, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: --|------|---|\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| Taltz\u00ae ELI LILLY AUSTRALIA PTY LTD | Non-radiographic axial spondyloarthritis | To request the PBAC review its November 2021 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n\n28\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SECUKINUMAB |  |  |\n| Injection 75 mg in 0.5 mL pre-filled syringe Injection 150 mg in 1 mL pre-filled pen Injection 300 mg in 2 mL pre-filled syringe Injection 300 mg in 2 mL pre-filled pen Cosentyx\u00ae | Paediatric psoriasis | To request the PBAC review its November 2021 recommendation that has not yet been accepted by the applicant. |\n| NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LTD |  |  |\n| (Review of positive PBAC recommendations not accepted by applicants) Review of PBS items for nurse practitioner and endorsed midwife prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners and endorsed midwives as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 6\n\nItems added or amended\n\n1. 2.\n\nIVACAFTOR (Kalydeco\u00ae) - Form(s) amended\n\nTARLATAMAB (Imdelltra\u00ae) \u2013 To be considered at a future PBAC Meeting\n\nItems added or amended previously\n\n3.\n\n4.\n\n5.\n\nALIROCUMAB (Praluent\u00ae) - R\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>", "estimated_coverage": 0.0}, {"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe provided evidence does not contain the answer.\n...", "total_latency_sec": 4.326}
{"timestamp": "2025-07-31T12:14:18.179668Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: ABALOPARATIDE hassponsor THERAMEX AUSTRALIA PTY LTD.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1-38\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1-38)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table details submissions for the July 2025 PBAC meeting, specifically focusing on reviews of positive PBAC recommendations not yet accepted by applicants.  It includes Galcanezumab for treatment-resistant high frequency episodic migraine, Hyaluronic Acid with Polyethylene Glycol 400 with Propylene Glycol with Hydroxypropyl Guar for severe dry eye syndrome, Mirikizumab for ulcerative colitis, and Mobocertinib.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table details new drug submissions for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC) for the November 2025 meeting. Submissions include retifanlimab (Zynyz\u00ae) by Specialised Therapeutics for Merkel cell carcinoma and squamous cell anal carcinoma, and risdiplam (Evrysdi\u00ae) by Roche for spinal muscular atrophy.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 2, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 2, 20, 22, 25, 28, 3, 37, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table from the November 2025 PBAC Meeting agenda details several drug submissions, including zanubrutinib for MCL, WM, CLL, and SLL; daratumumab for AL amyloidosis in combination with other drugs; and elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta\u00ae) for cystic fibrosis. The submissions aim to either list new drug forms or assess the utilization of existing PBS-listed medications for these conditions.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe sponsor for Abaloparatide is Theramex Australia Pty Ltd. <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing...", "total_latency_sec": 7.1}
{"timestamp": "2025-07-31T12:14:30.683396Z", "query": "What is Amivantamab used to treat?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: AMIVANTAMAB hasindication Non-small cell lung cancer (NSCLC).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1-30\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1-30)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nAmivantamab is used to treat Non-small cell lung cancer (NSCLC). <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/...", "total_latency_sec": 5.437}
{"timestamp": "2025-07-31T12:14:43.573244Z", "query": "What is the trade name for Dostarlimab?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: DOSTARLIMAB hastradename Jemperli\u00ae.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1-14\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page 1-14)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: This table presents the agenda for the November 2025 PBAC meeting, detailing drug submissions for new PBS listings or changes to existing listings.  It includes Spesolimab for generalized pustular psoriasis flares, Tafasitamab for relapsed and/or refractory follicular lymphoma, and Testosterone for hypoactive sexual desire dysfunction in postmenopausal women.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the July 2025 PBAC meeting, focusing on Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) and a request for a Section 100 listing for APDS.  It details several drugs (Eliglustat, Imiglucerase, Taliglucerase Alfa, Velaglucerase Alfa) and their submission types for PBS listing consideration.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents the agenda for the March 2025 PBAC meeting, detailing drug submissions, including new listings and changes to existing listings.  It includes ZOLBETUXIMAB for gastric or gastroesophageal junction cancer and ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR for cystic fibrosis.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents the agenda for the March 2025 PBAC meeting, detailing new drug submissions and listing requests.  It includes drugs like Dupilumab (Dupixent\u00ae) for atopic dermatitis and asthma in children, Efgartigimod alfa (Vyvgart\u00ae) for myasthenia gravis, and Eflornithine (Ifinwil\u00ae) for neuroblastoma.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents the agenda for the May 2025 PBAC meeting, detailing submissions for new or amended listings of Repotrectinib, Teprotumumab, and Trastuzumab Deruxtecan for various cancer and thyroid eye disease indications. The meeting also includes a submission for Ublituximab for relapsing-remitting multiple sclerosis.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 2, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: ral Schedule Authority Required listings of two aflibercept biosimilars for the treatment of RVO, DMO, and CNV due to AMD under the same conditions as their respective reference biologic.  To request General Schedule Authority Required (STREAMLINED) and Section 100 (Highly Specialised Drugs Program) Authority Required (STREAMLINED) listings of Movapo\u00ae POD, administered via an infusion pump with a collar attachment, under the existing listings for Apomine Solution for Infusion for the treatment of Parkinson's disease. |\n|  |  |  |\n| (New PBS listing) |  |  |\n\n4\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nJuly 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| ARIPIPRAZOLE |  |  |\n| Powder for injection 300 mg (as monohydrate) with diluent in pre-filled dual- chamber syringe Powder for injection 400 mg (as monohydrate) with diluent in pre-filled dual- chamber syringe Abilify Maintena\u00ae LUNDBECK AUSTRALIA PTY LTD (New PBS listing) BRENTUXIMAB VEDOTIN Powder for I.V. infusion 50 mg Adcetris\u00ae TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD. (Change to existing listing) | Schizophrenia   Hodgkin lymphoma | To request General Schedule Authority Required (STREAMLINED) listings of two new forms for the treatment of schizophrenia.   Resubmission to request a Section 100 (Efficient Funding of Chemotherapy) Authority Required (Written) listing for the first line treatment of advanced Hodgkin lymphoma in combination with chemotherapy. |\n\n5\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nJuly 2025\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents a list of drugs being considered for listing or changes to existing listings, including Elacestrant for breast cancer, Elafibranor for PBC, and Elexacaftor/Tezacaftor/Ivacaftor for cystic fibrosis. Each entry includes the drug's form, strength, trade name, sponsor, and the specific listing requested by the sponsor.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the November 2025 PBAC meeting, detailing drug submissions, including Durvalumab for muscle invasive bladder cancer and Efgartigimod alfa for generalized myasthenia gravis.  The submissions specify the requested listing type and authority level.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the November 2025 PBAC meeting, detailing new drug submissions and listing requests for encorafenib, binimetinib, estradiol with progesterone, and fedratinib for various indications like NSCLC, vasomotor symptoms, and myelofibrosis.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: Novo Nordisk Pharmaceuticals Pty. Ltd. has resubmitted a request to list Semaglutide (Wegovy\u00ae) on the PBS General Schedule for the treatment of patients with established cardiovascular disease (eCVD) and overweight or obesity.  The submission seeks Authority Required (Telephone/Online) listing status.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nThe trade name for Dostarlimab is Jemperli\u00ae. <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetin...", "total_latency_sec": 5.67}
{"timestamp": "2025-07-31T12:14:53.843521Z", "query": "What is the dosage form of Apomorphine?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: Apomorphine hasdosageform Injection containing apomorphine hydrochloride hemihydrate 100 mg.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1-38\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1-38)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table details various dosage forms and combinations of Elexacaftor, Tezacaftor, and Ivacaftor, including tablets and sachets with different strengths of each component, packaged together for administration under the trade name Trikafta\u00ae by Vertex Pharmaceuticals (Australia) Pty. Ltd.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 2, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nApomorphine has an injection dosage form containing apomorphine hydrochloride hemihydrate 100 mg. <a href=\"https://storage.googleapis.com/fresh...", "total_latency_sec": 5.82}
{"timestamp": "2025-07-31T12:15:01.605551Z", "query": "Which sponsors made submissions in both the March 2025 and July 2025 meetings?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 2, 20, 22, 25, 28, 3, 37, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 2, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table details submissions for the July 2025 PBAC meeting, specifically focusing on reviews of positive PBAC recommendations not yet accepted by applicants.  It includes Galcanezumab for treatment-resistant high frequency episodic migraine, Hyaluronic Acid with Polyethylene Glycol 400 with Propylene Glycol with Hydroxypropyl Guar for severe dry eye syndrome, Mirikizumab for ulcerative colitis, and Mobocertinib.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Pharmaceuticals Pty. Ltd. for paediatric patients with growth hormone deficiency. One submission was withdrawn.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe provided evidence does not contain the answer.\n...", "total_latency_sec": 5.722}
{"timestamp": "2025-07-31T12:15:04.641425Z", "query": "Compare the submission purposes for Acalabrutinib and Alectinib in the 2025 meetings.", "persona": "automatic", "intent": "classification_failed", "graph_suitable": "unknown", "tool_plan": [], "tool_results": [], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nI had trouble understanding the query....", "total_latency_sec": 1.642}
{"timestamp": "2025-07-31T12:15:10.285451Z", "query": "What is the indication for the drug whose trade name is Cabometyx?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nI searched but could not find any relevant details....", "total_latency_sec": 3.582}
{"timestamp": "2025-07-31T12:15:17.230998Z", "query": "Provide a summary of the key submissions from the May 2025 PBAC meeting.", "persona": "automatic", "intent": "simple_summary", "graph_suitable": false, "tool_plan": [{"tool_name": "vector_search", "estimated_coverage": 0.5}, {"tool_name": "query_knowledge_graph", "estimated_coverage": 0.36}], "tool_results": [{"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Pharmaceuticals Pty. Ltd. for paediatric patients with growth hormone deficiency. One submission was withdrawn.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the Pharmaceutical Benefits Scheme (PBS). Submissions include Brexpiprazole for schizophrenia, Bulevirtide for chronic hepatitis D (resubmission), and Cabozantinib for pancreatic and extra-pancreatic neuroendocrine tumors. The closing date for consumer comments was May 28, 2025.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 2, 20, 22, 25, 28, 3, 37, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: --|------|---|\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| Taltz\u00ae ELI LILLY AUSTRALIA PTY LTD | Non-radiographic axial spondyloarthritis | To request the PBAC review its November 2021 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n\n28\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SECUKINUMAB |  |  |\n| Injection 75 mg in 0.5 mL pre-filled syringe Injection 150 mg in 1 mL pre-filled pen Injection 300 mg in 2 mL pre-filled syringe Injection 300 mg in 2 mL pre-filled pen Cosentyx\u00ae | Paediatric psoriasis | To request the PBAC review its November 2021 recommendation that has not yet been accepted by the applicant. |\n| NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LTD |  |  |\n| (Review of positive PBAC recommendations not accepted by applicants) Review of PBS items for nurse practitioner and endorsed midwife prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners and endorsed midwives as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 6\n\nItems added or amended\n\n1. 2.\n\nIVACAFTOR (Kalydeco\u00ae) - Form(s) amended\n\nTARLATAMAB (Imdelltra\u00ae) \u2013 To be considered at a future PBAC Meeting\n\nItems added or amended previously\n\n3.\n\n4.\n\n5.\n\nALIROCUMAB (Praluent\u00ae) - R\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>", "estimated_coverage": 0.0}, {"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe provided evidence does not contain the answer.\n...", "total_latency_sec": 4.847}
{"timestamp": "2025-07-31T12:15:21.365783Z", "query": "Summarize all submissions related to oncology in the March 2025 documents.", "persona": "automatic", "intent": "simple_summary", "graph_suitable": false, "tool_plan": [{"tool_name": "vector_search", "estimated_coverage": 0.5}, {"tool_name": "query_knowledge_graph", "estimated_coverage": 0.36}], "tool_results": [{"tool_name": "vector_search", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nI searched but could not find any relevant details....", "total_latency_sec": 2.906}
{"timestamp": "2025-07-31T12:17:23.104042Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: ABALOPARATIDE hassponsor THERAMEX AUSTRALIA PTY LTD.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1-38\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1-38)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table details submissions for the July 2025 PBAC meeting, specifically focusing on reviews of positive PBAC recommendations not yet accepted by applicants.  It includes Galcanezumab for treatment-resistant high frequency episodic migraine, Hyaluronic Acid with Polyethylene Glycol 400 with Propylene Glycol with Hydroxypropyl Guar for severe dry eye syndrome, Mirikizumab for ulcerative colitis, and Mobocertinib.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table details new drug submissions for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC) for the November 2025 meeting. Submissions include retifanlimab (Zynyz\u00ae) by Specialised Therapeutics for Merkel cell carcinoma and squamous cell anal carcinoma, and risdiplam (Evrysdi\u00ae) by Roche for spinal muscular atrophy.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 2, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 2, 20, 22, 25, 28, 3, 37, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table from the November 2025 PBAC Meeting agenda details several drug submissions, including zanubrutinib for MCL, WM, CLL, and SLL; daratumumab for AL amyloidosis in combination with other drugs; and elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta\u00ae) for cystic fibrosis. The submissions aim to either list new drug forms or assess the utilization of existing PBS-listed medications for these conditions.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe sponsor for Abaloparatide is Theramex Australia Pty Ltd. <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing...", "total_latency_sec": 8.724}
{"timestamp": "2025-07-31T12:18:22.487771Z", "query": "Which sponsors made submissions in both the March 2025 and July 2025 meetings?", "persona": "automatic", "intent": "classification_failed", "graph_suitable": "unknown", "tool_plan": [], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 2, 20, 22, 25, 28, 3, 37, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the Pharmaceutical Benefits Scheme (PBS). Submissions include Brexpiprazole for schizophrenia, Bulevirtide for chronic hepatitis D (resubmission), and Cabozantinib for pancreatic and extra-pancreatic neuroendocrine tumors. The closing date for consumer comments was May 28, 2025.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table details new drug submissions for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC) for the November 2025 meeting. Submissions include retifanlimab (Zynyz\u00ae) by Specialised Therapeutics for Merkel cell carcinoma and squamous cell anal carcinoma, and risdiplam (Evrysdi\u00ae) by Roche for spinal muscular atrophy.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table details several drug submissions for the November 2025 PBAC meeting, including requests for new listings (Zanubrutinib for various blood cancers) and changes to existing listings (Vedolizumab for Crohn's disease and ulcerative colitis, and Renastart for chronic renal failure).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>", "estimated_coverage": 0.0}, {"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the Pharmaceutical Benefits Scheme (PBS). Submissions include Brexpiprazole for schizophrenia, Bulevirtide for chronic hepatitis D (resubmission), and Cabozantinib for pancreatic and extra-pancreatic neuroendocrine tumors. The closing date for consumer comments was May 28, 2025.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 2, 20, 22, 25, 28, 3, 37, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Pharmaceuticals Pty. Ltd. for paediatric patients with growth hormone deficiency. One submission was withdrawn.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 2, 3, 4, 5, 6, 7, 8, 9)</a>", "estimated_coverage": 0.0}, {"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: This table details submissions for the July 2025 PBAC meeting, specifically focusing on reviews of positive PBAC recommendations not yet accepted by applicants.  It includes Galcanezumab for treatment-resistant high frequency episodic migraine, Hyaluronic Acid with Polyethylene Glycol 400 with Propylene Glycol with Hydroxypropyl Guar for severe dry eye syndrome, Mirikizumab for ulcerative colitis, and Mobocertinib.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The July 2025 PBAC meeting agenda includes Abaloparatide for the first-line treatment of severe established osteoporosis under a General Schedule Authority Required listing and Abiraterone Acetate, with further details to be provided in the subsequent table rows.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table presents an agenda for the November 2025 PBAC meeting, including submissions for Osimertinib and Pegcetacoplan.  AstraZeneca seeks an expanded listing for Osimertinib for first-line treatment of EGFRm NSCLC in combination with chemotherapy.  A listing is requested for Pegcetacoplan for treating bilateral GA secondary to AMD in eyes with an intact fovea and threatened central vision.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The May 2025 PBAC meeting agenda includes items related to a new listing request for RRMS treatment by Kirchmann Enterprises, review of ATAGI recommendations on pediatric pneumococcal schedule, utilization assessment of fluticasone furoate + umeclidinium + vilanterol for severe asthma, utilization review of medicines for gastrointestinal stromal tumour, and utilization review of zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 2, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA November 2025 PBAC MEETING\n\nClosing date for consumer comments 24 September 2025\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1)</a>\n---\nEvidence from document: PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nJuly 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1)</a>\n---\nEvidence from document: The PBAC meeting agenda for November 2025 includes a new NIP listing request from Merck Sharp & Dohme (Australia) Pty Ltd for a 21-valent pneumococcal conjugate vaccine. The submission aims to expand the current NIP coverage for preventing pneumococcal disease in adults, including specific groups based on age and medical risk conditions, with a focus on Aboriginal and Torres Strait Islander populations.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nMay 2025 PBAC MEETING\n\nClosing date for consumer comments 26 March 2025\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page 1)</a>\n---\nEvidence from document: PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nBased on the provided meeting agendas for March 2025 and July 2025, there were no sponsors who made submissions in both meetings.  Beigene...", "total_latency_sec": 13.474}
{"timestamp": "2025-07-31T12:18:53.240134Z", "query": "what did GKS subm iteed?", "persona": "automatic", "intent": "classification_failed", "graph_suitable": "unknown", "tool_plan": [], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 2, 20, 22, 25, 28, 3, 37, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the Pharmaceutical Benefits Scheme (PBS). Submissions include Brexpiprazole for schizophrenia, Bulevirtide for chronic hepatitis D (resubmission), and Cabozantinib for pancreatic and extra-pancreatic neuroendocrine tumors. The closing date for consumer comments was May 28, 2025.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Pharmaceuticals Pty. Ltd. for paediatric patients with growth hormone deficiency. One submission was withdrawn.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: --|------|---|\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| Taltz\u00ae ELI LILLY AUSTRALIA PTY LTD | Non-radiographic axial spondyloarthritis | To request the PBAC review its November 2021 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n\n28\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SECUKINUMAB |  |  |\n| Injection 75 mg in 0.5 mL pre-filled syringe Injection 150 mg in 1 mL pre-filled pen Injection 300 mg in 2 mL pre-filled syringe Injection 300 mg in 2 mL pre-filled pen Cosentyx\u00ae | Paediatric psoriasis | To request the PBAC review its November 2021 recommendation that has not yet been accepted by the applicant. |\n| NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LTD |  |  |\n| (Review of positive PBAC recommendations not accepted by applicants) Review of PBS items for nurse practitioner and endorsed midwife prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners and endorsed midwives as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 6\n\nItems added or amended\n\n1. 2.\n\nIVACAFTOR (Kalydeco\u00ae) - Form(s) amended\n\nTARLATAMAB (Imdelltra\u00ae) \u2013 To be considered at a future PBAC Meeting\n\nItems added or amended previously\n\n3.\n\n4.\n\n5.\n\nALIROCUMAB (Praluent\u00ae) - R\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table details several drug submissions for the November 2025 PBAC meeting, including requests for new listings (Zanubrutinib for various blood cancers) and changes to existing listings (Vedolizumab for Crohn's disease and ulcerative colitis, and Renastart for chronic renal failure).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>", "estimated_coverage": 0.0}, {"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 2, 20, 22, 25, 28, 3, 37, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Pharmaceuticals Pty. Ltd. for paediatric patients with growth hormone deficiency. One submission was withdrawn.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the Pharmaceutical Benefits Scheme (PBS). Submissions include Brexpiprazole for schizophrenia, Bulevirtide for chronic hepatitis D (resubmission), and Cabozantinib for pancreatic and extra-pancreatic neuroendocrine tumors. The closing date for consumer comments was May 28, 2025.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 2, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: --|------|---|\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| Taltz\u00ae ELI LILLY AUSTRALIA PTY LTD | Non-radiographic axial spondyloarthritis | To request the PBAC review its November 2021 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n\n28\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SECUKINUMAB |  |  |\n| Injection 75 mg in 0.5 mL pre-filled syringe Injection 150 mg in 1 mL pre-filled pen Injection 300 mg in 2 mL pre-filled syringe Injection 300 mg in 2 mL pre-filled pen Cosentyx\u00ae | Paediatric psoriasis | To request the PBAC review its November 2021 recommendation that has not yet been accepted by the applicant. |\n| NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LTD |  |  |\n| (Review of positive PBAC recommendations not accepted by applicants) Review of PBS items for nurse practitioner and endorsed midwife prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners and endorsed midwives as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 6\n\nItems added or amended\n\n1. 2.\n\nIVACAFTOR (Kalydeco\u00ae) - Form(s) amended\n\nTARLATAMAB (Imdelltra\u00ae) \u2013 To be considered at a future PBAC Meeting\n\nItems added or amended previously\n\n3.\n\n4.\n\n5.\n\nALIROCUMAB (Praluent\u00ae) - R\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>", "estimated_coverage": 0.0}, {"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 2, 20, 22, 25, 28, 3, 37, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table details submissions for the July 2025 PBAC meeting, specifically focusing on reviews of positive PBAC recommendations not yet accepted by applicants.  It includes Galcanezumab for treatment-resistant high frequency episodic migraine, Hyaluronic Acid with Polyethylene Glycol 400 with Propylene Glycol with Hydroxypropyl Guar for severe dry eye syndrome, Mirikizumab for ulcerative colitis, and Mobocertinib.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Pharmaceuticals Pty. Ltd. for paediatric patients with growth hormone deficiency. One submission was withdrawn.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 2, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table details several drug submissions for the November 2025 PBAC meeting, including requests for new listings (Zanubrutinib for various blood cancers) and changes to existing listings (Vedolizumab for Crohn's disease and ulcerative colitis, and Renastart for chronic renal failure).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 3, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 3, 30, 31, 32, 33, 34, 35, 36, 37, 38, 4, 5, 6, 7, 8, 9)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nBased on the available information, I cannot determine what GSK submitted. My search for GSK submissions in the March and July 2025 PBAC m...", "total_latency_sec": 10.612}
{"timestamp": "2025-07-31T12:24:16.604151Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: ABALOPARATIDE hassponsor THERAMEX AUSTRALIA PTY LTD.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1-38\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1-38)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: RIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Submission type amended\n\n30. TRIGLYCERIDES - MEDIUM CHAIN, FORMULA (Monogen\u00ae) \u2013 Added\n\n38\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=3\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 3, 8, 30, 38)</a>\n---\nEvidence from document: The table presents the agenda for the March 2025 PBAC meeting, detailing new drug submissions and listing requests.  It includes drugs like Dupilumab (Dupixent\u00ae) for atopic dermatitis and asthma in children, Efgartigimod alfa (Vyvgart\u00ae) for myasthenia gravis, and Eflornithine (Ifinwil\u00ae) for neuroblastoma.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details new drug submissions for the November 2025 PBAC meeting.  Tezepelumab (Tezspire\u00ae) is submitted by AstraZeneca Pty Ltd for severe uncontrolled asthma in patients 12+ years old. Tocilizumab (Avtozma\u00ae), a biosimilar, is submitted by Celltrion Healthcare Australia Pty Ltd for various indications mirroring the originator brand.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table presents an agenda for the November 2025 PBAC meeting, including submissions for Osimertinib and Pegcetacoplan.  AstraZeneca seeks an expanded listing for Osimertinib for first-line treatment of EGFRm NSCLC in combination with chemotherapy.  A listing is requested for Pegcetacoplan for treating bilateral GA secondary to AMD in eyes with an intact fovea and threatened central vision.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: iasis, and juvenile idiopathic arthritis. Resubmission to request a General Schedule Authority Required (STREAMLINED) listing for the treatment of patients with locally advanced or metastatic cholangiocarcinoma who have previously progressed on systemic therapy and have a fibroblast growth factor receptor 2 fusion or rearrangement. |\n\n10\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nJuly 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| GIVOSIRAN |  |  |\n| Solution for injection 189 mg in 1 mL Givlaari\u24c7 MEDISON PHARMA AUSTRALIA PTY LIMITED | Acute hepatic porphyria (AHP) | To request a General Schedule Authority Required (Written) listing for the initial treatment and an Authority Required (STREAMLINED) listing for the continuing treatment of AHP in adults and adolescents aged 12 years and older. |\n| (New PBS listing) GLOFITAMAB |  |  |\n| Solution concentrate for I.V. infusion 2.5 mg in 2.5 mL Solution concentrate for I.V. infusion 10 mg in 10 mL Columvi\u24c7 | Relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL) | To request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (Telephone/Online) listing for the treatment of patients with RR DLBCL. |\n| ROCHE PRODUCTS PTY LTD (New PBS listing) |  |  |\n\n11\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nJuly 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/cha\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table shows drug submissions for the March 2025 PBAC meeting, including new listings and listing changes. It details the drug name, usage, and the sponsor's requested listing type (unrestricted, restricted benefit, or authority required). Drugs mentioned include Infliximab, Ivacaftor, Lumasiran, and Midostaurin.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the November 2025 PBAC meeting, detailing submissions for Acalabrutinib and Aflibercept for new indications and a biosimilar listing, respectively.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the March 2025 PBAC meeting, detailing drug submissions, including new listings and changes to existing listings.  It includes ZOLBETUXIMAB for gastric or gastroesophageal junction cancer and ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR for cystic fibrosis.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the November 2025 PBAC meeting, detailing new drug submissions and listing requests for encorafenib, binimetinib, estradiol with progesterone, and fedratinib for various indications like NSCLC, vasomotor symptoms, and myelofibrosis.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the March 2025 PBAC meeting, detailing drug submissions for new or changed listings.  It includes Elranatamab (Elrexfio\u00ae) for relapsed or refractory multiple myeloma (RRMM) and Estetrol with Drospirenone, along with Trikafta\u00ae for cystic fibrosis (CF) with a request for a change to its existing listing.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe sponsor for Abaloparatide is Theramex Australia Pty Ltd [1].\n\n**References**\n1. <a href=\"https://storage.googleapis.com/fresh-start-in...", "total_latency_sec": 7.583}
{"timestamp": "2025-07-31T12:24:29.958985Z", "query": "What is Amivantamab used to treat?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: AMIVANTAMAB hasindication Non-small cell lung cancer (NSCLC).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1-30\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1-30)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nAmivantamab is used to treat non-small cell lung cancer (NSCLC) [1].\n\n**References**\n1. <a href=\"https://storage.googleapis.com/fresh-start-inp...", "total_latency_sec": 5.535}
{"timestamp": "2025-07-31T12:32:10.433246Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: ABALOPARATIDE hassponsor THERAMEX AUSTRALIA PTY LTD.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1-38\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1-38)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details submissions for the July 2025 PBAC meeting, specifically focusing on reviews of positive PBAC recommendations not yet accepted by applicants.  It includes Galcanezumab for treatment-resistant high frequency episodic migraine, Hyaluronic Acid with Polyethylene Glycol 400 with Propylene Glycol with Hydroxypropyl Guar for severe dry eye syndrome, Mirikizumab for ulcerative colitis, and Mobocertinib.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details new drug submissions for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC) for the November 2025 meeting. Submissions include retifanlimab (Zynyz\u00ae) by Specialised Therapeutics for Merkel cell carcinoma and squamous cell anal carcinoma, and risdiplam (Evrysdi\u00ae) by Roche for spinal muscular atrophy.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table from the November 2025 PBAC Meeting agenda details several drug submissions, including zanubrutinib for MCL, WM, CLL, and SLL; daratumumab for AL amyloidosis in combination with other drugs; and elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta\u00ae) for cystic fibrosis. The submissions aim to either list new drug forms or assess the utilization of existing PBS-listed medications for these conditions.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe sponsor for Abaloparatide is Theramex Australia Pty Ltd [1].\n\n**References**\n1. <a href=\"https://storage.googleapis.com/fresh-start-in...", "total_latency_sec": 7.91}
{"timestamp": "2025-07-31T12:32:26.647874Z", "query": "What is Amivantamab used to treat?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: AMIVANTAMAB hasindication Non-small cell lung cancer (NSCLC).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1-30\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1-30)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nAmivantamab is used to treat non-small cell lung cancer (NSCLC) [1].\n\n**References**\n1. <a href=\"https://storage.googleapis.com/fresh-start-inp...", "total_latency_sec": 5.485}
{"timestamp": "2025-07-31T12:35:35.672897Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: ABALOPARATIDE hassponsor THERAMEX AUSTRALIA PTY LTD.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1-38\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1-38)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details submissions for the July 2025 PBAC meeting, specifically focusing on reviews of positive PBAC recommendations not yet accepted by applicants.  It includes Galcanezumab for treatment-resistant high frequency episodic migraine, Hyaluronic Acid with Polyethylene Glycol 400 with Propylene Glycol with Hydroxypropyl Guar for severe dry eye syndrome, Mirikizumab for ulcerative colitis, and Mobocertinib.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details new drug submissions for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC) for the November 2025 meeting. Submissions include retifanlimab (Zynyz\u00ae) by Specialised Therapeutics for Merkel cell carcinoma and squamous cell anal carcinoma, and risdiplam (Evrysdi\u00ae) by Roche for spinal muscular atrophy.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table from the November 2025 PBAC Meeting agenda details several drug submissions, including zanubrutinib for MCL, WM, CLL, and SLL; daratumumab for AL amyloidosis in combination with other drugs; and elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta\u00ae) for cystic fibrosis. The submissions aim to either list new drug forms or assess the utilization of existing PBS-listed medications for these conditions.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe sponsor for Abaloparatide is Theramex Australia Pty Ltd [1].\n\n**References**\n1. <a href=\"https://storage.googleapis.com/fresh-start-in...", "total_latency_sec": 7.902}
{"timestamp": "2025-07-31T12:35:47.693792Z", "query": "What is Amivantamab used to treat?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: AMIVANTAMAB hasindication Non-small cell lung cancer (NSCLC).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1-30\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1-30)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nAmivantamab is used to treat non-small cell lung cancer (NSCLC) [1].\n\n**References**\n1. <a href=\"https://storage.googleapis.com/fresh-start-inp...", "total_latency_sec": 5.547}
{"timestamp": "2025-07-31T12:37:41.667826Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: ABALOPARATIDE hassponsor THERAMEX AUSTRALIA PTY LTD.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1-38\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1-38)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details submissions for the July 2025 PBAC meeting, specifically focusing on reviews of positive PBAC recommendations not yet accepted by applicants.  It includes Galcanezumab for treatment-resistant high frequency episodic migraine, Hyaluronic Acid with Polyethylene Glycol 400 with Propylene Glycol with Hydroxypropyl Guar for severe dry eye syndrome, Mirikizumab for ulcerative colitis, and Mobocertinib.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details new drug submissions for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC) for the November 2025 meeting. Submissions include retifanlimab (Zynyz\u00ae) by Specialised Therapeutics for Merkel cell carcinoma and squamous cell anal carcinoma, and risdiplam (Evrysdi\u00ae) by Roche for spinal muscular atrophy.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table from the November 2025 PBAC Meeting agenda details several drug submissions, including zanubrutinib for MCL, WM, CLL, and SLL; daratumumab for AL amyloidosis in combination with other drugs; and elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta\u00ae) for cystic fibrosis. The submissions aim to either list new drug forms or assess the utilization of existing PBS-listed medications for these conditions.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe sponsor for Abaloparatide is Theramex Australia Pty Ltd [1].\n\n**References**\n1. <a href=\"https://storage.googleapis.com/fresh-start-in...", "total_latency_sec": 7.367}
{"timestamp": "2025-07-31T12:37:53.264934Z", "query": "What is Amivantamab used to treat?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: AMIVANTAMAB hasindication Non-small cell lung cancer (NSCLC).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1-30\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1-30)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nAmivantamab is used to treat non-small cell lung cancer (NSCLC) [1].\n\n**References**\n1. <a href=\"https://storage.googleapis.com/fresh-start-inp...", "total_latency_sec": 7.68}
{"timestamp": "2025-07-31T12:38:58.729020Z", "query": "Which sponsors made submissions in both the March 2025 and July 2025 meetings?", "persona": "automatic", "intent": "classification_failed", "graph_suitable": "unknown", "tool_plan": [], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the Pharmaceutical Benefits Scheme (PBS). Submissions include Brexpiprazole for schizophrenia, Bulevirtide for chronic hepatitis D (resubmission), and Cabozantinib for pancreatic and extra-pancreatic neuroendocrine tumors. The closing date for consumer comments was May 28, 2025.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details new drug submissions for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC) for the November 2025 meeting. Submissions include retifanlimab (Zynyz\u00ae) by Specialised Therapeutics for Merkel cell carcinoma and squamous cell anal carcinoma, and risdiplam (Evrysdi\u00ae) by Roche for spinal muscular atrophy.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}, {"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the Pharmaceutical Benefits Scheme (PBS). Submissions include Brexpiprazole for schizophrenia, Bulevirtide for chronic hepatitis D (resubmission), and Cabozantinib for pancreatic and extra-pancreatic neuroendocrine tumors. The closing date for consumer comments was May 28, 2025.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Pharmaceuticals Pty. Ltd. for paediatric patients with growth hormone deficiency. One submission was withdrawn.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nBased on the provided information, Novo Nordisk Pharmaceuticals Pty Limited made a submission in the March 2025 PBAC meeting [2].  However...", "total_latency_sec": 11.128}
{"timestamp": "2025-07-31T12:39:40.194235Z", "query": "What is the dosage form of Apomorphine?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: Apomorphine hasdosageform Injection containing apomorphine hydrochloride hemihydrate 100 mg.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1-38\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1-38)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table details various dosage forms and combinations of Elexacaftor, Tezacaftor, and Ivacaftor, including tablets and sachets with different strengths of each component, packaged together for administration under the trade name Trikafta\u00ae by Vertex Pharmaceuticals (Australia) Pty. Ltd.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nThe dosage form of Apomorphine is an injection containing apomorphine hydrochloride hemihydrate 100 mg [1].\n\n**References**\n1. <a href=\"https:/...", "total_latency_sec": 5.672}
{"timestamp": "2025-07-31T12:40:05.219148Z", "query": "Based on the agendas, what appears to be the main focus of the PBAC's work in 2025?", "persona": "automatic", "intent": "classification_failed", "graph_suitable": "unknown", "tool_plan": [], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the Pharmaceutical Benefits Scheme (PBS). Submissions include Brexpiprazole for schizophrenia, Bulevirtide for chronic hepatitis D (resubmission), and Cabozantinib for pancreatic and extra-pancreatic neuroendocrine tumors. The closing date for consumer comments was May 28, 2025.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table details several drug submissions for the November 2025 PBAC meeting, including requests for new listings (Zanubrutinib for various blood cancers) and changes to existing listings (Vedolizumab for Crohn's disease and ulcerative colitis, and Renastart for chronic renal failure).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents an agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the Pharmaceutical Benefits Scheme (PBS). Submissions include Brexpiprazole for schizophrenia, Bulevirtide for chronic hepatitis D (resubmission), and Cabozantinib for pancreatic and extra-pancreatic neuroendocrine tumors. The closing date for consumer comments was May 28, 2025.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Pharmaceuticals Pty. Ltd. for paediatric patients with growth hormone deficiency. One submission was withdrawn.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}, {"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The PBAC agenda primarily consists of applications relating to the new listing of a drug or vaccine on the Pharmaceutical Benefits Scheme (PBS) or the National Immunisation Program (NIP).\n\nThe PBAC agenda consists of the following:\n\n1 Minutes of Previous Meeting\n\n2 Chair's report (verbal)\n\n3 Matters arising from the minutes\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1)</a>\n---\nEvidence from document: The PBAC agenda primarily consists of applications relating to the new listing of a drug or vaccine on the Pharmaceutical Benefits Scheme (PBS) or the National Immunisation Program (NIP).\n\nThe PBAC agenda consists of the following:\n\n1 Minutes of Previous Meeting\n\n2 Chair's report (verbal)\n\n3 Matters arising from the minutes\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page 1)</a>\n---\nEvidence from document: The PBAC agenda primarily consists of applications relating to the new listing of a drug or vaccine on the Pharmaceutical Benefits Scheme (PBS) or the National Immunisation Program (NIP).\n\nThe PBAC agenda consists of the following:\n\n1 Minutes of Previous Meeting\n\n2 Chair's report (verbal)\n\n3 Matters arising from the minutes\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1)</a>\n---\nEvidence from document: The PBAC agenda primarily consists of applications relating to the new listing of a drug or vaccine on the Pharmaceutical Benefits Scheme (PBS) or the National Immunisation Program (NIP).\n\nThe PBAC agenda consists of the following:\n\n1 Minutes of Previous Meeting\n\n2 Chair's report (verbal)\n\n3 Matters arising from the minutes\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1)</a>\n---\nEvidence from document: The table presents the agenda for the November 2025 PBAC meeting, including submissions for changes to existing listings and new listings for National Immunisation Program (NIP) inclusion.  GlaxoSmithKline Australia Pty Ltd requests a change to the existing NIP listing for Shingrix\u00ae, a recombinant zoster vaccine, to lower the eligible age for non-Indigenous adults from 65 to 60 years. Moderna Australia Pty Ltd seeks a new NIP listing for mResvia\u00ae, a respiratory syncytial virus (RSV) vaccine, for individuals over 75 years and Aboriginal and Torres Strait Islander people over 60 years.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The July 2025 PBAC meeting agenda includes Abaloparatide for the first-line treatment of severe established osteoporosis under a General Schedule Authority Required listing and Abiraterone Acetate, with further details to be provided in the subsequent table rows.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table from the May 2025 PBAC Meeting Agenda outlines requests for new or amended listings of Pegcetacoplan for Paroxysmal nocturnal haemoglobinuria (PNH) and Pioglitazone for Type 2 diabetes mellitus (T2DM) on the Pharmaceutical Benefits Scheme (PBS).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The PBAC meeting agenda for November 2025 includes a new NIP listing request from Merck Sharp & Dohme (Australia) Pty Ltd for a 21-valent pneumococcal conjugate vaccine. The submission aims to expand the current NIP coverage for preventing pneumococcal disease in adults, including specific groups based on age and medical risk conditions, with a focus on Aboriginal and Torres Strait Islander populations.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA November 2025 PBAC MEETING\n\nClosing date for consumer comments 24 September 2025\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1)</a>\n---\nEvidence from document: PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nJuly 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1)</a>", "estimated_coverage": 0.0}, {"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nBased on the agendas available for March, May, and July 2025, the PBAC's main focus appears to be the evaluation of new drug and vaccine a...", "total_latency_sec": 11.54}
{"timestamp": "2025-07-31T12:40:54.475070Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: ABALOPARATIDE hassponsor THERAMEX AUSTRALIA PTY LTD.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1-38\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1-38)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details submissions for the July 2025 PBAC meeting, specifically focusing on reviews of positive PBAC recommendations not yet accepted by applicants.  It includes Galcanezumab for treatment-resistant high frequency episodic migraine, Hyaluronic Acid with Polyethylene Glycol 400 with Propylene Glycol with Hydroxypropyl Guar for severe dry eye syndrome, Mirikizumab for ulcerative colitis, and Mobocertinib.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details new drug submissions for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC) for the November 2025 meeting. Submissions include retifanlimab (Zynyz\u00ae) by Specialised Therapeutics for Merkel cell carcinoma and squamous cell anal carcinoma, and risdiplam (Evrysdi\u00ae) by Roche for spinal muscular atrophy.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table from the November 2025 PBAC Meeting agenda details several drug submissions, including zanubrutinib for MCL, WM, CLL, and SLL; daratumumab for AL amyloidosis in combination with other drugs; and elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta\u00ae) for cystic fibrosis. The submissions aim to either list new drug forms or assess the utilization of existing PBS-listed medications for these conditions.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe sponsor for Abaloparatide is Theramex Australia Pty Ltd [1].\n\n**References**\n1. <a href=\"https://storage.googleapis.com/fresh-start-in...", "total_latency_sec": 7.904}
{"timestamp": "2025-07-31T12:41:23.166621Z", "query": "What is Amivantamab used to treat?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: AMIVANTAMAB hasindication Non-small cell lung cancer (NSCLC).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1-30\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1-30)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nAmivantamab is used to treat non-small cell lung cancer (NSCLC) [1].\n\n**References**\n1. <a href=\"https://storage.googleapis.com/fresh-start-inp...", "total_latency_sec": 10.173}
{"timestamp": "2025-07-31T12:41:40.473615Z", "query": "What is the trade name for Dostarlimab?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: DOSTARLIMAB hastradename Jemperli\u00ae.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1-14\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page 1-14)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: This table presents the agenda for the November 2025 PBAC meeting, detailing drug submissions for new PBS listings or changes to existing listings.  It includes Spesolimab for generalized pustular psoriasis flares, Tafasitamab for relapsed and/or refractory follicular lymphoma, and Testosterone for hypoactive sexual desire dysfunction in postmenopausal women.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the July 2025 PBAC meeting, focusing on Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) and a request for a Section 100 listing for APDS.  It details several drugs (Eliglustat, Imiglucerase, Taliglucerase Alfa, Velaglucerase Alfa) and their submission types for PBS listing consideration.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the March 2025 PBAC meeting, detailing drug submissions, including new listings and changes to existing listings.  It includes ZOLBETUXIMAB for gastric or gastroesophageal junction cancer and ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR for cystic fibrosis.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the March 2025 PBAC meeting, detailing new drug submissions and listing requests.  It includes drugs like Dupilumab (Dupixent\u00ae) for atopic dermatitis and asthma in children, Efgartigimod alfa (Vyvgart\u00ae) for myasthenia gravis, and Eflornithine (Ifinwil\u00ae) for neuroblastoma.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the May 2025 PBAC meeting, detailing submissions for new or amended listings of Repotrectinib, Teprotumumab, and Trastuzumab Deruxtecan for various cancer and thyroid eye disease indications. The meeting also includes a submission for Ublituximab for relapsing-remitting multiple sclerosis.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: ral Schedule Authority Required listings of two aflibercept biosimilars for the treatment of RVO, DMO, and CNV due to AMD under the same conditions as their respective reference biologic.  To request General Schedule Authority Required (STREAMLINED) and Section 100 (Highly Specialised Drugs Program) Authority Required (STREAMLINED) listings of Movapo\u00ae POD, administered via an infusion pump with a collar attachment, under the existing listings for Apomine Solution for Infusion for the treatment of Parkinson's disease. |\n|  |  |  |\n| (New PBS listing) |  |  |\n\n4\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nJuly 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| ARIPIPRAZOLE |  |  |\n| Powder for injection 300 mg (as monohydrate) with diluent in pre-filled dual- chamber syringe Powder for injection 400 mg (as monohydrate) with diluent in pre-filled dual- chamber syringe Abilify Maintena\u00ae LUNDBECK AUSTRALIA PTY LTD (New PBS listing) BRENTUXIMAB VEDOTIN Powder for I.V. infusion 50 mg Adcetris\u00ae TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD. (Change to existing listing) | Schizophrenia   Hodgkin lymphoma | To request General Schedule Authority Required (STREAMLINED) listings of two new forms for the treatment of schizophrenia.   Resubmission to request a Section 100 (Efficient Funding of Chemotherapy) Authority Required (Written) listing for the first line treatment of advanced Hodgkin lymphoma in combination with chemotherapy. |\n\n5\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nJuly 2025\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents a list of drugs being considered for listing or changes to existing listings, including Elacestrant for breast cancer, Elafibranor for PBC, and Elexacaftor/Tezacaftor/Ivacaftor for cystic fibrosis. Each entry includes the drug's form, strength, trade name, sponsor, and the specific listing requested by the sponsor.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the November 2025 PBAC meeting, detailing drug submissions, including Durvalumab for muscle invasive bladder cancer and Efgartigimod alfa for generalized myasthenia gravis.  The submissions specify the requested listing type and authority level.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the November 2025 PBAC meeting, detailing new drug submissions and listing requests for encorafenib, binimetinib, estradiol with progesterone, and fedratinib for various indications like NSCLC, vasomotor symptoms, and myelofibrosis.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: Novo Nordisk Pharmaceuticals Pty. Ltd. has resubmitted a request to list Semaglutide (Wegovy\u00ae) on the PBS General Schedule for the treatment of patients with established cardiovascular disease (eCVD) and overweight or obesity.  The submission seeks Authority Required (Telephone/Online) listing status.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nThe trade name for Dostarlimab is Jemperli\u00ae [1].\n\n**References**\n1. <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listi...", "total_latency_sec": 9.956}
{"timestamp": "2025-07-31T12:41:51.618082Z", "query": "What is the dosage form of Apomorphine?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: Apomorphine hasdosageform Injection containing apomorphine hydrochloride hemihydrate 100 mg.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1-38\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1-38)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table details various dosage forms and combinations of Elexacaftor, Tezacaftor, and Ivacaftor, including tablets and sachets with different strengths of each component, packaged together for administration under the trade name Trikafta\u00ae by Vertex Pharmaceuticals (Australia) Pty. Ltd.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nThe dosage form of Apomorphine is an injection containing apomorphine hydrochloride hemihydrate 100 mg [1].\n\n**References**\n1. <a href=\"https:/...", "total_latency_sec": 9.76}
{"timestamp": "2025-07-31T12:42:12.540796Z", "query": "Which sponsors made submissions in both the March 2025 and July 2025 meetings?", "persona": "automatic", "intent": "classification_failed", "graph_suitable": "unknown", "tool_plan": [], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the Pharmaceutical Benefits Scheme (PBS). Submissions include Brexpiprazole for schizophrenia, Bulevirtide for chronic hepatitis D (resubmission), and Cabozantinib for pancreatic and extra-pancreatic neuroendocrine tumors. The closing date for consumer comments was May 28, 2025.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details new drug submissions for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC) for the November 2025 meeting. Submissions include retifanlimab (Zynyz\u00ae) by Specialised Therapeutics for Merkel cell carcinoma and squamous cell anal carcinoma, and risdiplam (Evrysdi\u00ae) by Roche for spinal muscular atrophy.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Pharmaceuticals Pty. Ltd. for paediatric patients with growth hormone deficiency. One submission was withdrawn.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}, {"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the Pharmaceutical Benefits Scheme (PBS). Submissions include Brexpiprazole for schizophrenia, Bulevirtide for chronic hepatitis D (resubmission), and Cabozantinib for pancreatic and extra-pancreatic neuroendocrine tumors. The closing date for consumer comments was May 28, 2025.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Pharmaceuticals Pty. Ltd. for paediatric patients with growth hormone deficiency. One submission was withdrawn.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nNone of the sponsors who made submissions to the March 2025 PBAC meeting (Beigene, Sanofi-Aventis, and Pfizer [1]) also made submissions t...", "total_latency_sec": 13.315}
{"timestamp": "2025-07-31T12:42:39.822920Z", "query": "Compare the submission purposes for Acalabrutinib and Alectinib in the 2025 meetings.", "persona": "automatic", "intent": "classification_failed", "graph_suitable": "unknown", "tool_plan": [], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Pharmaceuticals Pty. Ltd. for paediatric patients with growth hormone deficiency. One submission was withdrawn.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table details several drug submissions for the November 2025 PBAC meeting, including requests for new listings (Zanubrutinib for various blood cancers) and changes to existing listings (Vedolizumab for Crohn's disease and ulcerative colitis, and Renastart for chronic renal failure).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}, {"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Pharmaceuticals Pty. Ltd. for paediatric patients with growth hormone deficiency. One submission was withdrawn.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: --|------|---|\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| Taltz\u00ae ELI LILLY AUSTRALIA PTY LTD | Non-radiographic axial spondyloarthritis | To request the PBAC review its November 2021 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n\n28\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SECUKINUMAB |  |  |\n| Injection 75 mg in 0.5 mL pre-filled syringe Injection 150 mg in 1 mL pre-filled pen Injection 300 mg in 2 mL pre-filled syringe Injection 300 mg in 2 mL pre-filled pen Cosentyx\u00ae | Paediatric psoriasis | To request the PBAC review its November 2021 recommendation that has not yet been accepted by the applicant. |\n| NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LTD |  |  |\n| (Review of positive PBAC recommendations not accepted by applicants) Review of PBS items for nurse practitioner and endorsed midwife prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners and endorsed midwives as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 6\n\nItems added or amended\n\n1. 2.\n\nIVACAFTOR (Kalydeco\u00ae) - Form(s) amended\n\nTARLATAMAB (Imdelltra\u00ae) \u2013 To be considered at a future PBAC Meeting\n\nItems added or amended previously\n\n3.\n\n4.\n\n5.\n\nALIROCUMAB (Praluent\u00ae) - R\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nI could not find relevant information regarding the submission purposes for either Acalabrutinib or Alectinib in the 2025 PBAC (Pharmaceut...", "total_latency_sec": 15.137}
{"timestamp": "2025-07-31T12:43:06.343302Z", "query": "What is the indication for the drug whose trade name is Cabometyx?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Clinical Analyst**, here is what I found:\n\nI searched but could not find any relevant details....", "total_latency_sec": 10.357}
{"timestamp": "2025-07-31T12:43:33.182171Z", "query": "Provide a summary of the key submissions from the May 2025 PBAC meeting.", "persona": "automatic", "intent": "classification_failed", "graph_suitable": "unknown", "tool_plan": [], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the Pharmaceutical Benefits Scheme (PBS). Submissions include Brexpiprazole for schizophrenia, Bulevirtide for chronic hepatitis D (resubmission), and Cabozantinib for pancreatic and extra-pancreatic neuroendocrine tumors. The closing date for consumer comments was May 28, 2025.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Pharmaceuticals Pty. Ltd. for paediatric patients with growth hormone deficiency. One submission was withdrawn.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nI have identified the submissions being considered at the May 2025 PBAC meeting as Flutcasone furoate + umeclidinium + vilanterol (Trelegy...", "total_latency_sec": 24.16}
{"timestamp": "2025-07-31T12:44:30.590380Z", "query": "Summarize all submissions related to oncology in the March 2025 documents.", "persona": "automatic", "intent": "classification_failed", "graph_suitable": "unknown", "tool_plan": [], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the Pharmaceutical Benefits Scheme (PBS). Submissions include Brexpiprazole for schizophrenia, Bulevirtide for chronic hepatitis D (resubmission), and Cabozantinib for pancreatic and extra-pancreatic neuroendocrine tumors. The closing date for consumer comments was May 28, 2025.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Pharmaceuticals Pty. Ltd. for paediatric patients with growth hormone deficiency. One submission was withdrawn.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table details several drug submissions for the November 2025 PBAC meeting, including requests for new listings (Zanubrutinib for various blood cancers) and changes to existing listings (Vedolizumab for Crohn's disease and ulcerative colitis, and Renastart for chronic renal failure).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe March 2025 PBAC meeting documents included a submission for Bevacizumab (Pfizer) for various cancers [1].  While a submission for Ixek...", "total_latency_sec": 11.169}
{"timestamp": "2025-07-31T12:44:36.845239Z", "query": "Summarize all submissions related to oncology in the March 2025 documents.", "persona": "automatic", "intent": "simple_summary", "graph_suitable": false, "tool_plan": [{"tool_name": "vector_search", "estimated_coverage": 0.5}, {"tool_name": "query_knowledge_graph", "estimated_coverage": 0.36}], "tool_results": [{"tool_name": "vector_search", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nI searched but could not find any relevant details....", "total_latency_sec": 4.444}
{"timestamp": "2025-07-31T12:44:56.259001Z", "query": "Based on the agendas, what appears to be the main focus of the PBAC's work in 2025?", "persona": "automatic", "intent": "classification_failed", "graph_suitable": "unknown", "tool_plan": [], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the Pharmaceutical Benefits Scheme (PBS). Submissions include Brexpiprazole for schizophrenia, Bulevirtide for chronic hepatitis D (resubmission), and Cabozantinib for pancreatic and extra-pancreatic neuroendocrine tumors. The closing date for consumer comments was May 28, 2025.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table details several drug submissions for the November 2025 PBAC meeting, including requests for new listings (Zanubrutinib for various blood cancers) and changes to existing listings (Vedolizumab for Crohn's disease and ulcerative colitis, and Renastart for chronic renal failure).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nJuly 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1)</a>\n---\nEvidence from document: The table presents the agenda for the November 2025 PBAC meeting, including submissions for changes to existing listings and new listings for National Immunisation Program (NIP) inclusion.  GlaxoSmithKline Australia Pty Ltd requests a change to the existing NIP listing for Shingrix\u00ae, a recombinant zoster vaccine, to lower the eligible age for non-Indigenous adults from 65 to 60 years. Moderna Australia Pty Ltd seeks a new NIP listing for mResvia\u00ae, a respiratory syncytial virus (RSV) vaccine, for individuals over 75 years and Aboriginal and Torres Strait Islander people over 60 years.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA November 2025 PBAC MEETING\n\nClosing date for consumer comments 24 September 2025\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1)</a>\n---\nEvidence from document: PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nMay 2025 PBAC MEETING\n\nClosing date for consumer comments 26 March 2025\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page 1)</a>\n---\nEvidence from document: PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1)</a>\n---\nEvidence from document: The PBAC meeting agenda for November 2025 includes a new NIP listing request from Merck Sharp & Dohme (Australia) Pty Ltd for a 21-valent pneumococcal conjugate vaccine. The submission aims to expand the current NIP coverage for preventing pneumococcal disease in adults, including specific groups based on age and medical risk conditions, with a focus on Aboriginal and Torres Strait Islander populations.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The Pharmaceutical Benefits Advisory Committee (PBAC) meeting agenda for November 2025 includes consumer comment deadlines and details about submissions for listing or changes to existing listings on the Pharmaceutical Benefits Scheme (PBS).  This includes Pembrolizumab for neoadjuvant and adjuvant treatment of head and neck squamous cell carcinoma (HNSCC) with a streamlined authority required request by Merck Sharp & Dohme (Australia) Pty Ltd, and a new pack size of polyethylene glycol 400 with propylene glycol eye drops (Systane\u00ae) for severe dry eye syndrome with a streamlined authority required request by Alcon Laboratories (Australia) Pty Ltd.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The PBAC agenda primarily consists of applications relating to the new listing of a drug or vaccine on the Pharmaceutical Benefits Scheme (PBS) or the National Immunisation Program (NIP).\n\nThe PBAC agenda consists of the following:\n\n1 Minutes of Previous Meeting\n\n2 Chair's report (verbal)\n\n3 Matters arising from the minutes\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1)</a>\n---\nEvidence from document: The PBAC agenda primarily consists of applications relating to the new listing of a drug or vaccine on the Pharmaceutical Benefits Scheme (PBS) or the National Immunisation Program (NIP).\n\nThe PBAC agenda consists of the following:\n\n1 Minutes of Previous Meeting\n\n2 Chair's report (verbal)\n\n3 Matters arising from the minutes\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1)</a>\n---\nEvidence from document: The PBAC agenda primarily consists of applications relating to the new listing of a drug or vaccine on the Pharmaceutical Benefits Scheme (PBS) or the National Immunisation Program (NIP).\n\nThe PBAC agenda consists of the following:\n\n1 Minutes of Previous Meeting\n\n2 Chair's report (verbal)\n\n3 Matters arising from the minutes\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1)</a>", "estimated_coverage": 0.0}, {"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nJuly 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1)</a>\n---\nEvidence from document: PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA November 2025 PBAC MEETING\n\nClosing date for consumer comments 24 September 2025\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Page 1)</a>\n---\nEvidence from document: PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Page 1)</a>\n---\nEvidence from document: The table presents the agenda for the November 2025 PBAC meeting, including new drug submissions for cetrorelix, delgocitinib, and denosumab biosimilars.  Cetrorelix is for Assisted Reproductive Technology, delgocitinib is for chronic hand eczema, and the denosumab biosimilars are for osteoporosis, giant cell tumor of bone, and bone metastases.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nMay 2025 PBAC MEETING\n\nClosing date for consumer comments 26 March 2025\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Page 1)</a>\n---\nEvidence from document: ral Schedule Authority Required listings of two aflibercept biosimilars for the treatment of RVO, DMO, and CNV due to AMD under the same conditions as their respective reference biologic.  To request General Schedule Authority Required (STREAMLINED) and Section 100 (Highly Specialised Drugs Program) Authority Required (STREAMLINED) listings of Movapo\u00ae POD, administered via an infusion pump with a collar attachment, under the existing listings for Apomine Solution for Infusion for the treatment of Parkinson's disease. |\n|  |  |  |\n| (New PBS listing) |  |  |\n\n4\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nJuly 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| ARIPIPRAZOLE |  |  |\n| Powder for injection 300 mg (as monohydrate) with diluent in pre-filled dual- chamber syringe Powder for injection 400 mg (as monohydrate) with diluent in pre-filled dual- chamber syringe Abilify Maintena\u00ae LUNDBECK AUSTRALIA PTY LTD (New PBS listing) BRENTUXIMAB VEDOTIN Powder for I.V. infusion 50 mg Adcetris\u00ae TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD. (Change to existing listing) | Schizophrenia   Hodgkin lymphoma | To request General Schedule Authority Required (STREAMLINED) listings of two new forms for the treatment of schizophrenia.   Resubmission to request a Section 100 (Efficient Funding of Chemotherapy) Authority Required (Written) listing for the first line treatment of advanced Hodgkin lymphoma in combination with chemotherapy. |\n\n5\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nJuly 2025\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, including consumer comment deadlines and details of drug submissions.  It includes requests for changes to existing listings (e.g., Ranibizumab for proliferative diabetic retinopathy) and new listings (e.g., Raxtozinameran for COVID-19 prevention in specific adult populations).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table presents an agenda for the November 2025 PBAC meeting, including submissions for Osimertinib and Pegcetacoplan.  AstraZeneca seeks an expanded listing for Osimertinib for first-line treatment of EGFRm NSCLC in combination with chemotherapy.  A listing is requested for Pegcetacoplan for treating bilateral GA secondary to AMD in eyes with an intact fovea and threatened central vision.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The July 2025 PBAC meeting agenda includes Abaloparatide for the first-line treatment of severe established osteoporosis under a General Schedule Authority Required listing and Abiraterone Acetate, with further details to be provided in the subsequent table rows.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table details drug submissions for the March 2025 PBAC meeting, including Bulevirtide for chronic hepatitis D, Cipaglucosidase alfa and Miglustat for late onset Pompe disease, and Dabrafenib with Trametinib for non-small cell lung cancer.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}, {"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe PBAC's 2025 meetings covered a wide range of therapeutic areas. While some specific medications like Zanubrutinib were discussed in mu...", "total_latency_sec": 16.909}
{"timestamp": "2025-07-31T12:45:12.661838Z", "query": "What was the final PBAC decision on Ribociclib from the July 2025 meeting?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Pharmaceuticals Pty. Ltd. for paediatric patients with growth hormone deficiency. One submission was withdrawn.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: --|------|---|\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| Taltz\u00ae ELI LILLY AUSTRALIA PTY LTD | Non-radiographic axial spondyloarthritis | To request the PBAC review its November 2021 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n\n28\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SECUKINUMAB |  |  |\n| Injection 75 mg in 0.5 mL pre-filled syringe Injection 150 mg in 1 mL pre-filled pen Injection 300 mg in 2 mL pre-filled syringe Injection 300 mg in 2 mL pre-filled pen Cosentyx\u00ae | Paediatric psoriasis | To request the PBAC review its November 2021 recommendation that has not yet been accepted by the applicant. |\n| NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LTD |  |  |\n| (Review of positive PBAC recommendations not accepted by applicants) Review of PBS items for nurse practitioner and endorsed midwife prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners and endorsed midwives as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 6\n\nItems added or amended\n\n1. 2.\n\nIVACAFTOR (Kalydeco\u00ae) - Form(s) amended\n\nTARLATAMAB (Imdelltra\u00ae) \u2013 To be considered at a future PBAC Meeting\n\nItems added or amended previously\n\n3.\n\n4.\n\n5.\n\nALIROCUMAB (Praluent\u00ae) - R\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nI found some information, but it did not seem relevant....", "total_latency_sec": 9.78}
{"timestamp": "2025-07-31T12:45:19.517840Z", "query": "What is the price of Tirzepatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.63}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Health Economist**, here is what I found:\n\nI searched but could not find any relevant details....", "total_latency_sec": 5.208}
{"timestamp": "2025-07-31T12:45:30.036591Z", "query": "What are the latest FDA guidelines on biosimilars?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": false, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details submissions to the July 2025 PBAC meeting for review of prior positive recommendations not yet accepted by the applicants.  Submissions include Exkivity\u00ae for non-small cell lung cancer by Takeda Pharmaceuticals Australia Pty Ltd, secukinumab (Cosentyx\u00ae) by Novartis Pharmaceuticals Australia Pty Ltd for various indications including non-radiographic axial spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, and somapacitan (Sogroya\u00ae) by Novo Nordisk Pharmaceuticals Pty. Ltd. for paediatric patients with growth hormone deficiency. One submission was withdrawn.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, including submissions for pioglitazone (Actos\u00ae) by Celltrion Healthcare Australia Pty Ltd for a new pack size and increased quantity for type 2 diabetes mellitus, and a resubmission by GlaxoSmithKline Australia Pty Ltd for Arexvy\u00ae for the prevention of lower respiratory tract disease caused by RSV in older adults.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: --|------|---|\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| Taltz\u00ae ELI LILLY AUSTRALIA PTY LTD | Non-radiographic axial spondyloarthritis | To request the PBAC review its November 2021 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n\n28\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nMarch 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SECUKINUMAB |  |  |\n| Injection 75 mg in 0.5 mL pre-filled syringe Injection 150 mg in 1 mL pre-filled pen Injection 300 mg in 2 mL pre-filled syringe Injection 300 mg in 2 mL pre-filled pen Cosentyx\u00ae | Paediatric psoriasis | To request the PBAC review its November 2021 recommendation that has not yet been accepted by the applicant. |\n| NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LTD |  |  |\n| (Review of positive PBAC recommendations not accepted by applicants) Review of PBS items for nurse practitioner and endorsed midwife prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners and endorsed midwives as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 6\n\nItems added or amended\n\n1. 2.\n\nIVACAFTOR (Kalydeco\u00ae) - Form(s) amended\n\nTARLATAMAB (Imdelltra\u00ae) \u2013 To be considered at a future PBAC Meeting\n\nItems added or amended previously\n\n3.\n\n4.\n\n5.\n\nALIROCUMAB (Praluent\u00ae) - R\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details submissions for the July 2025 PBAC meeting, specifically focusing on reviews of positive PBAC recommendations not yet accepted by applicants.  It includes Galcanezumab for treatment-resistant high frequency episodic migraine, Hyaluronic Acid with Polyethylene Glycol 400 with Propylene Glycol with Hydroxypropyl Guar for severe dry eye syndrome, Mirikizumab for ulcerative colitis, and Mobocertinib.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nI found some information, but it did not seem relevant....", "total_latency_sec": 8.323}
{"timestamp": "2025-07-31T23:38:14.564088Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: ABALOPARATIDE hassponsor THERAMEX AUSTRALIA PTY LTD.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1-38\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1-38)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: RIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Submission type amended\n\n30. TRIGLYCERIDES - MEDIUM CHAIN, FORMULA (Monogen\u00ae) \u2013 Added\n\n38\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=3\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 3, 8, 30, 38)</a>\n---\nEvidence from document: The table presents the agenda for the March 2025 PBAC meeting, detailing new drug submissions and listing requests.  It includes drugs like Dupilumab (Dupixent\u00ae) for atopic dermatitis and asthma in children, Efgartigimod alfa (Vyvgart\u00ae) for myasthenia gravis, and Eflornithine (Ifinwil\u00ae) for neuroblastoma.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details new drug submissions for the November 2025 PBAC meeting.  Tezepelumab (Tezspire\u00ae) is submitted by AstraZeneca Pty Ltd for severe uncontrolled asthma in patients 12+ years old. Tocilizumab (Avtozma\u00ae), a biosimilar, is submitted by Celltrion Healthcare Australia Pty Ltd for various indications mirroring the originator brand.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table presents an agenda for the November 2025 PBAC meeting, including submissions for Osimertinib and Pegcetacoplan.  AstraZeneca seeks an expanded listing for Osimertinib for first-line treatment of EGFRm NSCLC in combination with chemotherapy.  A listing is requested for Pegcetacoplan for treating bilateral GA secondary to AMD in eyes with an intact fovea and threatened central vision.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: iasis, and juvenile idiopathic arthritis. Resubmission to request a General Schedule Authority Required (STREAMLINED) listing for the treatment of patients with locally advanced or metastatic cholangiocarcinoma who have previously progressed on systemic therapy and have a fibroblast growth factor receptor 2 fusion or rearrangement. |\n\n10\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nJuly 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| GIVOSIRAN |  |  |\n| Solution for injection 189 mg in 1 mL Givlaari\u24c7 MEDISON PHARMA AUSTRALIA PTY LIMITED | Acute hepatic porphyria (AHP) | To request a General Schedule Authority Required (Written) listing for the initial treatment and an Authority Required (STREAMLINED) listing for the continuing treatment of AHP in adults and adolescents aged 12 years and older. |\n| (New PBS listing) GLOFITAMAB |  |  |\n| Solution concentrate for I.V. infusion 2.5 mg in 2.5 mL Solution concentrate for I.V. infusion 10 mg in 10 mL Columvi\u24c7 | Relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL) | To request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (Telephone/Online) listing for the treatment of patients with RR DLBCL. |\n| ROCHE PRODUCTS PTY LTD (New PBS listing) |  |  |\n\n11\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA\n\nJuly 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/cha\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table shows drug submissions for the March 2025 PBAC meeting, including new listings and listing changes. It details the drug name, usage, and the sponsor's requested listing type (unrestricted, restricted benefit, or authority required). Drugs mentioned include Infliximab, Ivacaftor, Lumasiran, and Midostaurin.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the November 2025 PBAC meeting, detailing submissions for Acalabrutinib and Aflibercept for new indications and a biosimilar listing, respectively.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the March 2025 PBAC meeting, detailing drug submissions, including new listings and changes to existing listings.  It includes ZOLBETUXIMAB for gastric or gastroesophageal junction cancer and ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR for cystic fibrosis.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the November 2025 PBAC meeting, detailing new drug submissions and listing requests for encorafenib, binimetinib, estradiol with progesterone, and fedratinib for various indications like NSCLC, vasomotor symptoms, and myelofibrosis.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the March 2025 PBAC meeting, detailing drug submissions for new or changed listings.  It includes Elranatamab (Elrexfio\u00ae) for relapsed or refractory multiple myeloma (RRMM) and Estetrol with Drospirenone, along with Trikafta\u00ae for cystic fibrosis (CF) with a request for a change to its existing listing.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe sponsor for Abaloparatide is Theramex Australia Pty Ltd [1].\n\n**References**\n1. <a href=\"https://storage.googleapis.com/fresh-start-in...", "total_latency_sec": 7.788}
{"timestamp": "2025-07-31T23:42:35.409066Z", "query": "What company is the sponsor for Abaloparatide?", "persona": "automatic", "intent": "specific_fact_lookup", "graph_suitable": true, "tool_plan": [{"tool_name": "query_knowledge_graph", "estimated_coverage": 0.81}, {"tool_name": "vector_search", "estimated_coverage": 0.5}], "tool_results": [{"tool_name": "query_knowledge_graph", "success": true, "content": "Evidence from graph: ABALOPARATIDE hassponsor THERAMEX AUSTRALIA PTY LTD.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1-38\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Page 1-38)</a>", "estimated_coverage": 0.0}, {"tool_name": "vector_search", "success": true, "content": "Evidence from document: The table presents an agenda for the March 2025 PBAC meeting, including items for discussion such as the utilization of Trikafta\u00ae for cystic fibrosis and other medications for severe asthma and gastrointestinal stromal tumors.  Some items are deferred for consideration to the May 2025 meeting.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details submissions for the July 2025 PBAC meeting, specifically focusing on reviews of positive PBAC recommendations not yet accepted by applicants.  It includes Galcanezumab for treatment-resistant high frequency episodic migraine, Hyaluronic Acid with Polyethylene Glycol 400 with Propylene Glycol with Hydroxypropyl Guar for severe dry eye syndrome, Mirikizumab for ulcerative colitis, and Mobocertinib.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table details new drug submissions for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC) for the November 2025 meeting. Submissions include retifanlimab (Zynyz\u00ae) by Specialised Therapeutics for Merkel cell carcinoma and squamous cell anal carcinoma, and risdiplam (Evrysdi\u00ae) by Roche for spinal muscular atrophy.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: eview of positive PBAC recommendations not accepted by applicants - Added AMIVANTAMAB (Rybrevant\u00ae), LAZERTINIB (Lazcluze\u00ae) \u2013 Drug name, form, and submission purpose amended BEVACIZUMAB (Zirabev\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n29\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING AGENDA March 2025 PBAC MEETING\n\nClosing date for consumer comments 29 January 2025\n\nCIPAGLUCOSIDASE ALFA (Pombiliti\u00ae), MIGLUSTAT (Opfolda\u00ae) - Drug name amended\n\n7. DABRAFENIB (Tafinlar\u00ae), TRAMETINIB (Mekinist\u00ae) \u2013 Drug name amended\n\n6.\n\n8.\n\nEFLORNITHINE (Ifinwil\u00ae) - Purpose of submission amended\n\n9.\n\nELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Submission purpose amended\n\n10. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta\u00ae) \u2013 Removed\n\n11. ELRANATAMAB (Elrexfio\u00ae) - Purpose of submission amended\n\n12. FLUTICASONE FUROATE + UMECLIDINIUM + VILANTEROL (Trelegy Ellipta\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n13.\n\nIXEKIZUMAB (Taltz\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. MEDICINES FOR GASTROINTESTINAL STROMAL TUMOUR (All brands) \u2013 To be considered at the May 2025 PBAC meeting\n\n15. NIRSEVIMAB (Beyfortus\u00ae) \u2013 Submission purpose amended, to be considered at the May 2025 PBAC meeting\n\n16. Review of PBS items for nurse practitioner and endorsed midwife prescribing (Various brands) - Added\n\n17. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n18. ZANUBRUTINIB (Brukinsa\u00ae) \u2013 To be considered at the May 2025 PBAC meeting\n\n30\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents an agenda for the May 2025 PBAC meeting, detailing drug submissions for consideration, including IncobotulinumtoxinA (Xeomin\u24c7) for chronic sialorrhea under the Botulinum Toxin Program, Nirsevimab (Beyfortus\u00ae) for RSV prevention in infants and young children (resubmission for NIP listing), and Nivolumab + Ipilimumab for an unspecified indication.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/May-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">May-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: consumer comments 28 May 2025\n\n| Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name\u00ae, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |\n|---|------|---|\n| SOMAPACITAN |  |  |\n| Injection 10 mg in 1.5 mL pre-filled pen Sogroya\u00ae |  |  |\n| NOVO NORDISK PHARMACEUTICALS PTY LIMITED | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |\n| (Review of positive PBAC recommendations not accepted by applicants) |  |  |\n| Review of PBS-listed medicines for nurse practitioner prescribing |  |  |\n| Various forms and strengths Various brands Various sponsors | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |\n| (Other matters) |  |  |\n\nVersion 5\n\n1.\n\n2.\n\n3.\n\nItems added or amended\n\nARIPIPRAZOLE (Abilify Maintena\u00ae) \u2013 Form(s) amended\n\nBULEVIRTIDE (Hepcludex\u00ae) - Added\n\nEPLERENONE (Inspra\u00ae) \u2013 Sponsor amended\n\n4.\n\nLife Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) - Forms and trade names amended\n\n5.\n\nLife Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Drug names, forms, and trade names amended\n\n6.\n\n7.\n\nReview of PBS-listed medicines for nurse practitioner prescribing (Various brands) \u2013 Added\n\n8.\n\n9.\n\nODEVIXIBAT (Bylvay\u00ae) \u2013 Added\n\nSOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Withdrawn TARLATAMAB (Imdelltra\u00ae) \u2013 Withdrawn\n\n37\n\nPHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETIN\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: G AGENDA July 2025 PBAC MEETING\n\nClosing date for consumer comments 28 May 2025\n\nItems added or amended previously\n\n10. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n11. CANNABIDIOL (Epidyolex\u00ae) - Purpose of submission amended\n\n12.\n\nFUTIBATINIB (Lytgobi\u00ae) \u2013 Added\n\n13. GALCANEZUMAB (Emgality\u00ae) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n14. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane\u00ae Hydration) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n15. INFLUENZA VACCINE (Fluad\u00ae, Flucelvax\u00ae) \u2013 Withdrawn\n\n16. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) \u2013 Added\n\n17. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 - Added\n\n18. MIRIKIZUMAB (Omvoh\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n19. MOBOCERTINIB (Exkivity\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n20. NIVOLUMAB (Opdivo\u00ae) + IPILIMUMAB (Yervoy\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n21. PALOPEGTERIPARATIDE (Yorvipath\u00ae) \u2013 Added\n\n22. PEMBROLIZUMAB (Keytruda\u00ae) \u2013 Unresectable advanced and metastatic cancer - Added\n\n23. PIOGLITAZONE (Actos\u24c7) \u2013 To be considered at the May 2025 PBAC meeting\n\n24. SECUKINUMAB (Cosentyx\u00ae) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n25. SOMAPACITAN (Sogroya\u00ae, Paediatric patients with growth hormone deficiency) - Review of positive PBAC recommendations not accepted by applicants - Added\n\n26. SOMAPACITAN (Sogroya\u00ae, Adult-onset growth hormone deficiency) \u2013 Review of positive PBAC recommendations not accepted by applicants - Added\n\n27. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) \u2013 Added\n\n28. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) \u2013 Form amended\n\n29. T\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table presents the agenda for the July 2025 PBAC meeting, detailing drug submissions for new or changed listings on the PBS/NIP.  It includes information on Fluad\u00ae and Flucelvax\u00ae for influenza prevention, Insulin Degludec (Tresiba\u00ae) for Type 1 diabetes mellitus, and Leniiolisib (Joenja\u00ae) for Activated PI3K delta syndrome.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/July-2025-PBAC-Meeting-v5.pdf#page=1\" target=\"_blank\">July-2025-PBAC-Meeting-v5 (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: This table from the November 2025 PBAC Meeting agenda details several drug submissions, including zanubrutinib for MCL, WM, CLL, and SLL; daratumumab for AL amyloidosis in combination with other drugs; and elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta\u00ae) for cystic fibrosis. The submissions aim to either list new drug forms or assess the utilization of existing PBS-listed medications for these conditions.\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/November-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">November-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>\n---\nEvidence from document: The table lists drug submissions for the March 2025 PBAC meeting, including new listings and reviews of previous recommendations.  Specifically, it includes Zanubrutinib for Waldenstr\u00f6m Macroglobulinaemia (Beigene), Alirocumab for hypercholesterolaemia (Sanofi-Aventis), Bevacizumab for various cancers (Pfizer), and Ixekizumab (submission details not provided).\nCitation: <a href=\"https://storage.googleapis.com/fresh-start-input/docai/input/listing/elements/pbac-meetings/agenda/pdf/2025/March-2025-PBAC-Meeting.pdf#page=1\" target=\"_blank\">March-2025-PBAC-Meeting (Pages 1, 2, 3, 4, ...)</a>", "estimated_coverage": 0.0}], "final_answer_preview": "Acting as a **Regulatory Specialist**, here is what I found:\n\nThe sponsor for Abaloparatide is Theramex Australia Pty Ltd [1].\n\n**References**\n1. <a href=\"https://storage.googleapis.com/fresh-start-in...", "total_latency_sec": 7.787}
